Arch Therapeutics (ARTH) S-1/A 20 Jun 24 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Mar. 31, 2024
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 5
Entity Registrant Name	ARCH THERAPEUTICS, INC.
Entity Central Index Key	0001537561
Entity Tax Identification Number	46-0524102
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	235 Walnut St., Suite 6
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01702
City Area Code	(617)
Local Phone Number	431-2313
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	235 Walnut St., Suite 6
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01702
City Area Code	(617)
Local Phone Number	431-2313
Contact Personnel Name	Terrence W. Norchi

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Cash	$ 26,426	$ 222,720	$ 746,940
Inventory	1,329,593	1,364,504	1,414,848
Prepaid expenses and other current assets	177,158	362,866	436,407
Total current assets	1,533,177	1,950,090	2,598,195
Long-term assets:
Property and equipment, net	3,390	4,599	2,044
Other assets	3,500	3,500	3,500
Total long-term assets	6,890	8,099	5,544
Total assets	1,540,067	1,958,189	2,603,739
Current liabilities:
Accounts payable	2,969,520	2,304,207	1,328,000
Accrued expenses and other liabilities	363,092	467,496	318,505
Accrued interest	1,026,963	823,128	127,781
Derivative liability, current portion			748,275
Total current liabilities	12,417,551	9,465,921	3,320,494
Long-term liabilities:
Accrued interest, long-term			204,575
Derivative liability, long-term			459,200
Total long-term liabilities			3,476,048
Total liabilities		9,465,921	6,796,542
Commitments and contingencies
Stockholders’ deficit:
Preferred stock
Common stock	4,444	4,689	1,252
Additional paid-in capital	55,324,472	54,543,188	50,878,718
Accumulated deficit	(66,206,400)	(62,055,609)	(55,072,773)
Total stockholders’ deficit	(10,877,484)	(7,507,732)	(4,192,803)
Total liabilities and stockholders’ deficit	1,540,067	1,958,189	2,603,739
Bridge Financing [Member].
Current liabilities:
Shareholders advances related to bridge financing	1,125,000
Insurance Premium Financing [Member]
Current liabilities:
Insurance premium financing	34,755	243,285	247,933
Senior Secured Convertible Notes [Member]
Current liabilities:
Current portion of convertible note	4,211,720	3,519,103
Long-term liabilities:
Noncurrent portion of convertible note			1,662,492
Unsecured Convertible Notes [Member]
Current liabilities:
Current portion of convertible note	2,686,501	1,658,702
Long-term liabilities:
Noncurrent portion of convertible note			699,781
Convertible Notes Payable Series Two [Member]
Current liabilities:
Current portion of convertible note		450,000	550,000
Long-term liabilities:
Noncurrent portion of convertible note			$ 450,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000	4,000,000
Common stock, shares issued	4,444,364	4,689,446	1,252,734
Common stock, shares outstanding	4,444,364	4,689,446	1,252,734

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 31,866	$ 16,654	$ 77,733	$ 22,914	$ 75,724	$ 15,652
Operating expenses:
Cost of revenues	21,555	18,718	45,161	36,353	78,163	51,489
Selling, general and administrative expenses	683,184	1,252,786	1,994,534	2,355,701	4,371,164	4,519,636
Research and development expenses	203,869	170,634	409,449	332,087	670,880	1,153,333
Total operating expenses	908,608	1,442,138	2,449,144	2,724,141	5,120,207	5,724,458
Loss from operations	(876,742)	(1,425,484)	(2,371,411)	(2,701,227)	(5,044,483)	(5,708,806)
Other (expense) income:
Interest expense	(592,397)	(635,190)	(1,779,380)	(1,159,503)	(3,096,550)	(567,048)
Change in fair value of derivative liability					1,158,197	1,000,000
Gain on extinguishment of derivative liabilities		1,158,197		1,158,197
Total other (expense) income, net	(592,397)	523,007	(1,779,380)	(1,306)	(1,938,353)	432,952
Net loss	$ (1,469,139)	$ (902,477)	$ (4,150,791)	$ (2,702,533)	$ (6,982,836)	$ (5,275,854)
Loss per share - basic and diluted
Net loss per common share, basic	$ (0.33)	$ (0.71)	$ (0.90)	$ (2.15)	$ (2.27)	$ (4.40)
Net loss per common share, diluted	$ (0.33)	$ (0.71)	$ (0.90)	$ (2.15)	$ (2.27)	$ (4.40)
Weighted common shares, basic	4,497,111	1,263,585	4,602,623	1,258,099	3,074,115	1,199,575
Weighted common shares, diluted	4,497,111	1,263,585	4,602,623	1,258,099	3,074,115	1,199,575

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2021		$ 1,186	$ 48,770,059	$ (49,796,919)	$ (1,025,674)
Balance, shares at Sep. 30, 2021		1,186,901
Net loss				(5,275,854)	(5,275,854)
Issuance of common stock and warrants, net of financing costs		$ 64	1,609,077		1,609,141
Issuance of common stock and warrants, net of financing costs, shares		63,833
Stock-based compensation expense			499,584		499,584
Vesting of restricted stock		$ 2	(2)
Vesting of restricted stock, shares		2,000
Balance at Sep. 30, 2022		$ 1,252	50,878,718	(55,072,773)	(4,192,803)
Balance, shares at Sep. 30, 2022		1,252,734
Net loss				(1,800,056)	(1,800,056)
Stock-based compensation expense			104,026		104,026
Balance at Dec. 31, 2022		$ 1,252	50,982,744	(56,872,829)	(5,888,833)
Balance, shares at Dec. 31, 2022		1,252,734
Balance at Sep. 30, 2022		$ 1,252	50,878,718	(55,072,773)	(4,192,803)
Balance, shares at Sep. 30, 2022		1,252,734
Net loss					(2,702,533)
Balance at Mar. 31, 2023		$ 1,275	51,387,943	(57,775,306)	(6,386,088)
Balance, shares at Mar. 31, 2023		1,274,601
Balance at Sep. 30, 2022		$ 1,252	50,878,718	(55,072,773)	(4,192,803)
Balance, shares at Sep. 30, 2022		1,252,734
Net loss				(6,982,836)	(6,982,836)
Issuance of common stock and warrants, net of financing costs		$ 3,345	2,206,495		2,209,840
Issuance of common stock and warrants, net of financing costs, shares		3,344,321
Issuance of common stock upon conversion of convertible notes		$ 60	718,858		718,918
Issuance of common stock upon conversion of convertible notes, shares		59,912
Issuance of common stock and warrants with convertible notes		$ 20	440,297		440,317
Issuance of common stock and warrants with convertible notes, shares		20,210
Exchange of warrants into common stock		$ 12	49,265		49,277
Exchange of warrants into common stock, shares		12,019
Stock-based compensation expense			249,555		249,555
Stock-based compensation expense, shares		250
Balance at Sep. 30, 2023		$ 4,689	54,543,188	(62,055,609)	(7,507,732)
Balance, shares at Sep. 30, 2023		4,689,446
Balance at Dec. 31, 2022		$ 1,252	50,982,744	(56,872,829)	(5,888,833)
Balance, shares at Dec. 31, 2022		1,252,734
Net loss				(902,477)	(902,477)
Issuance of common stock and warrants, net of financing costs		$ 10	287,410		287,420
Issuance of common stock and warrants, net of financing costs, shares		9,598
Exchange of warrants into common stock		$ 13	49,265		49,278
Exchange of warrants into common stock, shares		12,019
Stock-based compensation expense			68,524		68,524
Vesting of restricted stock
Vesting of restricted stock, shares		250
Balance at Mar. 31, 2023		$ 1,275	51,387,943	(57,775,306)	(6,386,088)
Balance, shares at Mar. 31, 2023		1,274,601
Balance at Sep. 30, 2023		$ 4,689	54,543,188	(62,055,609)	(7,507,732)
Balance, shares at Sep. 30, 2023		4,689,446
Net loss				(2,681,652)	(2,681,652)
Issuance of common stock upon conversion of convertible notes		$ 53	587,906		587,959
Issuance of common stock upon conversion of convertible notes, shares		52,918
Stock-based compensation expense			25,909		25,909
Balance at Dec. 31, 2023		$ 4,742	55,157,003	(64,737,261)	(9,575,516)
Balance, shares at Dec. 31, 2023		4,742,364
Balance at Sep. 30, 2023		$ 4,689	54,543,188	(62,055,609)	(7,507,732)
Balance, shares at Sep. 30, 2023		4,689,446
Net loss					(4,150,791)
Balance at Mar. 31, 2024		$ 4,444	55,324,472	(66,206,400)	(10,877,484)
Balance, shares at Mar. 31, 2024		4,444,364
Balance at Dec. 31, 2023		$ 4,742	55,157,003	(64,737,261)	(9,575,516)
Balance, shares at Dec. 31, 2023		4,742,364
Net loss				(1,469,139)	(1,469,139)
Issuance of common stock and warrants, net of financing costs			148,891		148,891
Issuance of common stock and warrants, net of financing costs, shares
Issuance of common stock upon conversion of convertible notes		$ 2	18,278		18,280
Issuance of common stock upon conversion of convertible notes, shares		2,000
Exchange of warrants into common stock		$ (300)	300
Exchange of warrants into common stock, shares		(300,000)
Balance at Mar. 31, 2024		$ 4,444	$ 55,324,472	$ (66,206,400)	$ (10,877,484)
Balance, shares at Mar. 31, 2024		4,444,364

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (4,150,791)	$ (2,702,533)	$ (6,982,836)	$ (5,275,854)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	1,209	1,043	1,966	3,196
Stock-based compensation	25,909	172,550	249,555	499,583
Change in fair value of derivative liability			(1,158,197)	(1,000,000)
Inventory obsolescence charge				248,073
Amortization of debt discount			2,310,860	302,049
Gain on extinguishment of derivative liabilities		(1,158,197)
Accretion of discount and debt issuance costs on convertible notes payable	1,437,588	846,147
Changes in operating asset and liabilities:
Inventory	34,911	12,464	50,344	(569,156)
Prepaid expenses and other current assets	185,707	280,058	421,091	225,124
Accounts payable	665,314	1,097,894	976,207	846,869
Accrued interest	341,793	313,356	659,690	265,000
Accrued expenses and other liabilities	(104,404)	(112,713)	97,104	(959)
Net cash used in operating activities	(1,562,764)	(1,249,931)	(3,374,216)	(4,456,075)
Cash flows from investing activities:
Purchases of property and equipment			(4,521)
Net cash used in investing activities			(4,521)
Cash flows from financing activities:
Repayment of insurance premium financing	(208,530)	(212,514)	(350,322)	(106,257)
Proceeds received from senior secured convertible notes, net of financing costs				3,042,633
Proceeds from unsecured convertible notes	450,000	515,000	995,000
Shareholder advances related to bridge financing	1,125,000	230,000
Proceeds from issued common stock and warrants, net of financing costs			2,209,839
Net cash provided by financing activities	1,366,470	532,486	2,854,517	2,936,376
Net decrease in cash	(196,294)	(717,445)	(524,220)	(1,519,699)
Cash, beginning of period	222,720	746,940	746,940	2,266,639
Cash, end of period	26,426	29,495	222,720	746,940
Non-cash financing activities:
Financing of insurance premium			347,550	354,190
Issuance of restricted stock		3,019		8,959
Fair value of placement agent warrants - second close				1,470,133
Fair value of inducement shares issued - second close		25,840		25,840
Exchange of Series G and Series H warrants for common stock		49,278
Relative fair value of warrants issued – fourth close	148,891
Exchange of Series 2 Convertible Notes into Senior Secured Notes (See Note 6)				699,781
Issuance of restricted stock in consideration for services performed				30,840
Unpaid issuance costs in accounts payable			110,576	73,048
Conversion of convertible notes and accrued interest to common stock, net	606,239		606,239
Conversion Of Series 2 Convertible Notes And Interest Into Common Stock [Member]
Non-cash financing activities:
Conversion of convertible notes and accrued interest to common stock, net	606,239		606,239
Issued With Notes Payable [Member]
Non-cash financing activities:
Fair value of placement agent warrants - second close			1,159,247
Common Stock Warrants [Member]
Non-cash financing activities:
Fair value of inducement shares issued - second close			49,277
Placement Agent Warrant 2022 [Member]
Non-cash financing activities:
Fair value of placement agent warrants - second close				219,894
Second Warrants [Member]
Non-cash financing activities:
Fair value of placement agent warrants - second close		256,439		256,439
Placement Agent Warrants [Member]
Non-cash financing activities:
Fair value of placement agent warrants - second close		$ 28,093		28,093
Inducement Shares 2022 [Member]
Non-cash financing activities:
Fair value of inducement shares issued - second close				$ 314,523

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arch Therapeutics, Inc. (together with its subsidiary, the “Company” or “Arch”) is a biotechnology company developing and marketing a products based on our innovative AC5® self-assembling technology platform. Arch is the result of the merger (the “Merger”) of three entities on June 26, 2013, previously known as Arch Biosurgery, Inc., Almah, Inc., and Arch Acquisition Corporation, respectively. Arch Biosurgery, Inc. (ABS) is a biotechnology company that was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006 as Clear Nano Solutions, Inc., and changed its name from Clear Nano Solutions, Inc. to Arch Therapeutics, Inc. on April 7, 2008, and, as part of the Merger transaction, changed its name from Arch Therapeutics, Inc. to Arch Biosurgery. Almah, Inc., was incorporated under the laws of the State of Nevada on September 16, 2009 and, as part of the Merger transaction, changed its name to Arch Therapeutics, Inc. and abandoned both its prior business plan and operations in order to adopt those of ABS. Arch Acquisition Corporation, or Merger Sub, was a wholly owned subsidiary of Almah, Inc., formed for the purpose of the Merger transaction, pursuant to which Merger Sub merged with and into ABS, and ABS thereafter became the wholly owned subsidiary of the Company. The ticker symbol under which its Common Stock trades changed from “AACH” to “ARTH”, accordingly. The Company’s principal offices are located in Framingham, Massachusetts. We believe these that our products can be important advances in the field of stasis and barrier applications, which includes managing wounds created during surgery, trauma or interventional care, or from disease; stopping bleeding (hemostasis); and controlling leaking (sealant). We have recently devoted a substantial part of our operational effort to the market adoption and commercial sales of AC5 Advanced Wound System, our first product. Our goal is to make care faster and safer for patients by providing products for use on external wounds, which we refer to as Dermal Sciences applications, and products for use inside the body, which we refer to as BioSurgery applications. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has not yet generated sufficient revenues to fund operations and relies on issuance of debt and equity instruments to generate working capital. As reflected in the accompanying financial statements, for the year ended September 30, 2023, the Company recorded a net loss of $ 6,982,836 3,374,216 In evaluating the going concern position of the Company, management has considered potential funding providers and believes that financing to fund future operations could be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Arch Therapeutics, Inc. (together with its subsidiary, the “Company” or “Arch”) is a biotechnology company developing and marketing products based on our innovative AC5® self-assembling technology platform. The Company’s products are in the field of stasis and barrier applications, which includes managing wounds created during surgery, trauma or interventional care, or from disease; stopping bleeding (hemostasis); and controlling leaking (sealant). Basis of presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the three and six months ended March 31, 2024 and 2023. The balance sheet as of September 30, 2023 is derived from the Company’s audited financial statements. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending September 30, 2024. In accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating decision maker (the Company’s President and Chief Executive Officer) determined that the Company has only one The condensed consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has not yet generated sufficient revenues to fund operations and relies on issuance of debt and equity instruments to generate working capital. As reflected in the accompanying financial statements, for the six months ended March 31, 2024, the Company recorded a net loss of $ 4,150,791 1,562,764 The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its current and its potential future products. The Company has not yet generated sufficient revenues to fund operations and relies on issuance of debt and equity instruments to generate working capital. In evaluating the going concern position of the Company, management has considered potential funding providers and believes that financing to fund future operations could be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. Reverse stock split On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1: 200 Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Revenue The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third-party warehouse. In circumstances where the transaction price is not able to be determined at the time of shipment, the Company does not recognize revenue or any receivable amount until such time that the final transaction price is established. Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the Company’s awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the condensed consolidated financial statements, is based on awards that are ultimately expected to vest. Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures At March 31, 2024 and September 30, 2023, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Series Convertible Notes, 2022 Notes, Second Notes, Third Notes and the Fourth Notes approximate fair value because borrowing rates and terms are similar to comparable market participants. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company has determined that the warrants issued in June 2018 and May 2019 equity financing (see Note 3) meet the requirements for liability classification. During the three months ended March 31, 2023, $ 1,158,197 12,019 49,278 Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the periods ended March 31, 2024 and 2023, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES March 31, 2024 March 31, 2023 Stock options 88,275 104,325 Stock warrants 26,724,240 847,021 Convertible notes payable 754,744 721,790 Total 27,567,259 1,673,136 Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. Risks and uncertainties – Geopolitical Conflicts The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may be impacted by the outbreak of geopolitical conflicts. The Company’s ability to obtain future inventory may be impacted, therefore potentially affecting the Company’s future revenue stream. In addition, the Company has historically and principally funded its operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of Common Stock and warrants which may also be impacted by economic conditions beyond the Company’s control as well as uncertainties resulting from geopolitical conflicts. The extent to which recent events, including recent wars in Ukraine and Israel/Gaza, will impact the global economy and the Company is uncertain and cannot be reasonably measured.	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1: 200 In accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating decision maker (the Company’s President and Chief Executive Officer) determined that the Company has only one Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Revenue recognition In accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue upon shipment from the Company’s third-party warehouse which is when control of the product is transferred to the customers. In circumstances where the transaction price is not able to be determined at the time of shipment, the Company does not recognize revenue or any receivable amount until such time that the final transaction price is established and shipped to customer. Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and 2022. Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out (“FIFO”) basis. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The Company records adjustments to its inventory for estimated obsolescence or diminution in net realizable value equal to the difference between the cost of the inventory and the estimated net realizable value. When evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period in which it occurs. Once inventory has been written down, it creates a new cost basis for inventory that may not subsequently written up. For the year ended September 30, 2023 there was no 248,073 Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with FASB ASC Topic 360, Property, Plant and Equipment Leases The Company determines whether a contract is, or contains, a lease at inception. Operating lease right-of-use (“ ROU The Company leases its office facility on a month to month basis with a monthly lease of approximately $ 3,500 Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 . Complex Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option-pricing model or other acceptable valuation models, including Monte-Carlo simulations. Derivative instruments are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is re-assessed at the end of each reporting period. The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants, including options or warrants to non-employees in exchange for consulting or other services performed. The Company accounts for its common stock warrants in accordance with Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging Income Taxes In accordance with FASB ASC Topic 740, Income Taxes ASC 740 The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of our awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the consolidated financial statements, is based on awards that are ultimately expected to vest. Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the years ended September 30, 2023 and 2022, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES September 30, 2023 September 30, 2022 Stock Options 102,125 98,626 Stock Warrants 26,284,002 806,452 Convertible notes payable 738,763 652,202 Unvested restricted common stock - 250 Total 27,124,890 1,557,530 Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company’s own views about the assumptions market participants would use in pricing the asset or liability. At September 30, 2023 and 2022, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Company’s convertible notes (see Notes 6,7, and 8) approximate fair value because borrowing rates and terms are similar to comparable market participants. Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. During the year ended September 30, 2023, the Company reclassified the carrying amount of Exchange Notes of $ 699,781 Recent Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective October 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

INVENTORIES

INVENTORIES	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORIES	2 INVENTORIES Inventories consist of the following: SCHEDULE OF INVENTORIES March 31, September 30, 2024 2023 Finished Goods $ 65,980 $ 40,969 Goods-in-Process 1,263,613 1,323,535 Total $ 1,329,593 $ 1,364,504 Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out (“FIFO”) basis. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The Company records adjustments to its inventory for estimated obsolescence or diminution in net realizable value equal to the difference between the cost of the inventory and the estimated net realizable value. Once inventory has been written down, it creates a new cost basis for inventory that may not be subsequently written up. For the periods ended March 31, 2024 and 2023, the Company did no	3 INVENTORIES Inventories consist of the following: SCHEDULE OF INVENTORIES September 30, September 30, 2023 2022 Finished Goods $ 40,969 $ 9,063 Goods-in-process 1,323,535 1,405,785 Total $ 1,364,504 $ 1,414,848

INSURANCE PREMIUM FINANCING

INSURANCE PREMIUM FINANCING	12 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
INSURANCE PREMIUM FINANCING	4. INSURANCE PREMIUM FINANCING During July 2023 and 2022, the Company entered into a financing agreement with First Insurance Funding to fund a portion of its insurance policies. As part of the agreement, First Insurance Funding agreed to finance the insurance policies of the Company of approximately $ 395,000 354,000 8.7 2.99 35,000 The outstanding balance as of September 30, 2023 and 2022 was $ 243,285 247,933

WARRANT DERIVATIVE LIABILITY

WARRANT DERIVATIVE LIABILITY	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Warrant Derivative Liability
WARRANT DERIVATIVE LIABILITY	3. WARRANT DERIVATIVE LIABILITY As of March 31, 2024 and September 30, 2023, there are no The Company previously issued warrants (Series G and Series H warrants) that were accounted for the in accordance with ASC 815-10 as the Company is required to purchase the Series G, and Series H warrants for an amount of cash per share equal to $ 22.00 10.66 During the three months ended March 31, 2023, the Company issued 12,019 49,278 1,158,197	5. DERIVATIVE LIABILITIES WARRANT DERIVATIVE LIABILITY In June 2018 and May 2019, the Company issued its Series F Warrants, Series G Warrants, and Series H Warrants. Pursuant to the terms of the respective warrant agreements, the Company was required to purchase its Series F Warrants, Series G Warrants and Series H Warrants for an amount of cash equal to $ 36.00 22.00 10.66 As of September 30, 2021, the estimated fair value of the derivative liabilities was $ 2,207,475 1,000,000 1,207,475 On March 10, 2023, the Company entered into exchange agreements with the holders of the Series G Warrants and the Series H Warrants. Pursuant to the exchange agreements, the warrant holders exchanged 34,013 3,402 43,077 8,617 49,277 1,158,197 Fair Value Measurements Using Significant Unobservable Inputs - Year Ended September 30, 2023 SCHEDULE OF FAIR VALUE MEASUREMENTS (Level 3) Series G Series H Total Beginning balance at September 30, 2022 $ 748,275 $ 459,200 $ 1,207,475 Exchange of warrants into common stock (13,947 ) (35,330 ) (49,277 ) Extinguishment of derivative liabilities (734,328 ) (423,870 ) (1,158,197 ) Ending balance at September 30, 2023 $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs - Year Ended September 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Beginning balance $ 1,000,000 $ 748,275 $ 459,200 Expiration of derivative liability (1,000,000 ) — — Ending balance at September 30, 2022 $ — $ 748,275 $ 459,200 Ending balance $ — $ 748,275 $ 459,200 As of March 10, 2023 and September 30, 2022, the derivative liabilities were valued at the greater of their minimum value or by using the Black Scholes option pricing model with the following assumptions: SCHEDULE OF DERIVATIVE LIABILITIES Series G Series H Series G Series H Date of valuation March 10, 2023 September 30, 2022 Closing price per share of Common Stock $ 4.10 $ 4.10 $ 3.84 $ 3.84 Exercise price per share $ 140.00 $ 80.00 $ 140.00 $ 80.00 Expected volatility 179.41 % 141.03 % 132.97 % 122.50 % Risk-free interest rate 4.91 % 4.75 % 4.05 % 4.14 % Dividend yield — — — — Valuation assumptions - - - - Remaining expected term of underlying securities (years) 0.24 1.31 0.69 1.57

CONVERTIBLE NOTES PAYABLE, SENI

CONVERTIBLE NOTES PAYABLE, SENIOR SECURED	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE, SENIOR SECURED	4. CONVERTIBLE NOTES PAYABLE, SENIOR SECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Senior Secured Convertible Promissory Notes (the “2022 Notes”) $ 4,211,720 $ 4,230,000 Unamortized debt discount - (710,897 ) Net Balance $ 4,211,720 $ 3,519,103 In July 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited individual investors and issued Senior Secured Convertible Promissory Notes (the “2022 Notes”) in the aggregate of $ 4,230,000 3,525,000 705,000 The 2022 Notes are secured by tangible and intangible assets of the Company, bears interest at a rate of 10 9.14 The 2022 Notes contain customary events of default. Further, events of default under the 2022 Notes also include (i) the unavailability of Rule 144 on or after January 6, 2023; (ii) our failure to deliver the shares of common stock to the 2022 Note holder upon exercise by such holder of its conversion rights under the 2022 Note; (iii) our loss of the “bid” price for its common stock and/or a market and such loss is not cured during the specified cure periods; and (iv) our failure to complete an uplisting of our Common Stock to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by April 30, 2024 (the “Uplist Transaction”). During the year ended September 2023, for no additional consideration, the 2022 Notes were amended several times in order to allow the Company to issue additional notes payable, extend the completion date for the Uplist Transaction, and amend certain provisions with regards to mandatory conversion of the notes upon the Uplist Transaction. In connection with the issuance of the 2022 Notes, the Company granted the 2022 Notes noteholders 425,555 9.94 5 1,470,000 63,834 315,000 31,510 10.06 5 108,000 271,000 The Company recorded 2022 Notes with total principal of $ 4,230,000 2,870,000 705,000 1,578,000 315,000 271,000 As of September 30, 2023, outstanding balance of the 2022 Notes payable was $ 4,230,000 710,897 3,519,103 On December 26, 2023, the Company issued a total of 2,000 18,280 On February 14, 2024, the Company entered into an amendment to the 2022 Notes, under which 95 % of the principal amount of the Notes shall automatically convert, upon the closing of an Uplist Transaction, as defined, with a conversion price of $ 0.50 per share, into pre-funded warrants with an exercise price of $ 0.000125 per share, exercisable immediately. In addition, the note holder shall receive a warrant to purchase 80 times the dollar amount of the notes that are converted, with an exercise price per share of $ 0.50 During the three and six months ended March 31, 2024, the Company amortized debt discount of $ 46,965 710,897 4,211,720 no	6. CONVERTIBLE NOTES PAYABLE, SENIOR SECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED September 30, 2023 September 30, 2022 Senior Secured Convertible Promissory Notes (the “2022 Notes”, includes $ 96,000 $ 4,230,000 $ 4,230,000 Unamortized debt discount (710,897 ) (2,567,508 ) Net Balance 3,519,103 1,662,492 Current Balance (3,519,103 ) - Non-Current Balance - 1,662,492 In July 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited individual investors and issued Senior Secured Convertible Promissory Notes (the “2022 Notes”) in the aggregate of $ 4,230,000 3,525,000 705,000 The 2022 Notes are secured by tangible and intangible assets of the Company, bears interest at a rate of 10 9.14 In connection with the issuance of the 2022 Notes, the Company granted the 2022 Notes noteholders 425,562 9.94 5 1,470,000 63,842 315,000 31,510 10.06 5 219,894 555,414 The Company recorded 2022 Notes with total principal of $ 4,230,000 2,870,000 705,000 1,470,000 315,000 555,414 302,000 As of September 30, 2022, outstanding balance of the 2022 Notes payable was $ 4,230,000 2,567,508 1,662,492 1,857,000 4,230,000 710,897 3,519,103 96,000

CONVERTIBLE NOTES PAYABLE, UNSE

CONVERTIBLE NOTES PAYABLE, UNSECURED	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Convertible Notes Payable Unsecured
CONVERTIBLE NOTES PAYABLE, UNSECURED	5. CONVERTIBLE NOTES PAYABLE, UNSECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED March 31, 2024 September 30, 2023 Exchanged notes (July 2022) $ 699,781 $ 699,781 Second closing notes (January 2023) 636,000 636,000 Third closing notes (March, April, May, 2023) 702,720 702,720 Fourth closing notes (March, 2024) 648,000 - Total 2,686,501 2,038,501 Unamortized debt discount - (379,799 ) Net balance $ 2,686,501 $ 1,658,702 Exchanged Notes (July 2022) In relation to the issuance of the 2022 Notes (see Note 4), certain noteholders of the Company’s Series 2 note payable agreed to exchange their Series 2 notes payable consisting of $ 600,000 99,781 699,781 10 June 30, 2024 9.14 no Second Closing Notes (January 2023) In January 2023, the Company issued Unsecured Convertible Promissory Notes (the “Second Closing Notes”) in the aggregate of $ 636,000 530,000 106,000 10 9.14 In connection with the issuance of the Second Closing Notes, the Company granted the Second Closing Notes noteholders 127,968 9,598 9.94 5 256,000 9,598 26,000 6,565 10.06 5 13,000 31,000 On February 14, 2024, the Company entered into an amendment to the Second Closing Notes, under which 95 0.50 0.000125 0.50 Third Closing Notes (March, April and May 2023) In March, April and May 2023, the Company issued Unsecured Convertible Promissory Notes (the “Third Closing Notes”) in the aggregate of $ 703,000 488,000 215,000 10 June 30, 2024 9.14 In connection with the issuance of the Third Closing Notes, the Company granted the Third Closing Notes noteholders 141,396 10,608 9.94 5 164,000 10,608 18,000 5,000 The Second Closing Notes and Third Closing Notes contain events of default similar to the 2022 Notes. Subsequent to issuance, for no additional consideration, the Second Closing Notes and Third Closing Notes were amended several times in order to allow the Company to issue additional notes payable, extend the completion date of the Uplist Transaction, and amend certain provisions with regards mandatory conversion of the notes upon the Uplist Transaction. On February 14, 2024, the Company entered into an amendment to the Third Closing Notes, under which 95 0.50 0.000125 0.50 Fourth Closing Notes (March 2024) On March 12, 2024, investors agreed to purchase Unsecured Convertible Promissory Notes (the “Fourth Closing Notes”) in the aggregate principal amount of $ 648,000 450,000 198,000 10 9.14 In connection with the issuance of the Fourth Closing Notes, the Company granted the Fourth Closing Notes noteholders 130,383 9,782 9.94 5 0.001 148,891 On February 14, 2024, the Company entered into an amendment to the Fourth Closing Notes, under which 95 0.50 0.000125 0.50	7. CONVERTIBLE NOTES PAYABLE, UNSECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED September 30, 2023 September 30, 2022 Exchanged notes (July 2022) $ 699,781 $ 699,781 Second closing notes (January 2023) 636,000 - Third closing notes (March, April, May, 2023) 702,720 - Total 2,038,501 $ 699,781 Unamortized debt discount (379,799 ) - Net Balance 1,658,702 699,781 Current Balance (1,658,702 ) - Non-Current Balance - 699,781 Exchanged Notes (July 2022) In relation to the issuance of the 2022 Notes (see Note 6), certain noteholders of the Company’s Series 2 note payable (see Note 8) agreed to exchange their Series 2 notes payable consisting of $ 600,000 99,781 699,781 10 January 6, 2024 9.14 Second Closing Notes (January 2023) In January 2023, pursuant to the SPA (see Note 6), as amended, investors agreed to purchase Unsecured Convertible Promissory Notes (the “Second Closing Notes”) in the aggregate of $ 636,000 530,000 106,000 10 9.14 In connection with the issuance of the Second Closing Notes, the Company granted the Second Closing Notes noteholders (i) 127,968 9.94 5 256,000 9,598 26,000 6,565 10.06 5 13,000 31,000 Third Closing Notes (March, April and May 2023) In March, April and May 2023, pursuant to the SPA, as amended, investors agreed to purchase Unsecured Convertible Promissory Notes (the “Third Closing Notes”) in the aggregate of $ 703,000 488,000 215,000 10 9.14 In connection with the issuance of the Third Closing Notes, the Company granted the Third Closing Notes noteholders (i) 141,396 9.94 5 164,000 10,608 18,000 5,000 The Second Closing Notes and Third Closing Notes contain events of default similar to the 2022 Notes (See Note 6). Subsequent to issuance, for no additional consideration, the Second Closing Notes and Third Closing Notes were amended several times in order to allow the Company to issue additional notes payable, extend the completion date of the Uplist Transaction, and amend certain provisions with regards mandatory conversion of the notes upon the Uplist Transaction. Debt discount on unsecured convertible promissory notes As a result of the issuance of the Second Closing and the Third Closing Notes, the Company recorded debt discount in the aggregate of $ 834,000 321,000 433,000 44,000 36,000 During the year ended September 30, 2023, the Company amortized debt discount of $ 454,000 2,039,000 380,000 1,659,000 The warrants issued with the 2022 Notes, the Second Closing Notes, and the Third Closing Notes were valued using the Black Scholes option pricing model with the following assumptions: SCHEDULE OF SHARE BASED PAYMENT AWARD AND WARRANTS VALUATION ASSUMPTIONS Note Placement Note Placement Note First closing Second Closing Third Closing Note Placement Note Placement Note Date of valuation July 6, 2022 January 18, 2023 May 15, 2023 Closing price per share of Common Stock $ 9.98 $ 9.98 $ 5.76 $ 5.76 $ 2.77 Exercise price per share $ 9.94 $ 10.06 $ 9.94 $ 10.06 $ 9.94 Expected volatility 88.44 % 88.44 % 111.31 % 111.31 % 114.33 % Risk-free interest rate 2.96 % 2.96 % 3.43 % 3.43 % 3.46 % Dividend yield — — — — — Valuation assumptions - - - - - Remaining expected term of underlying securities (years) 5.0 5.0 5.0 5.0 5.0

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
CONVERTIBLE NOTES PAYABLE	4. CONVERTIBLE NOTES PAYABLE, SENIOR SECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Senior Secured Convertible Promissory Notes (the “2022 Notes”) $ 4,211,720 $ 4,230,000 Unamortized debt discount - (710,897 ) Net Balance $ 4,211,720 $ 3,519,103 In July 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited individual investors and issued Senior Secured Convertible Promissory Notes (the “2022 Notes”) in the aggregate of $ 4,230,000 3,525,000 705,000 The 2022 Notes are secured by tangible and intangible assets of the Company, bears interest at a rate of 10 9.14 The 2022 Notes contain customary events of default. Further, events of default under the 2022 Notes also include (i) the unavailability of Rule 144 on or after January 6, 2023; (ii) our failure to deliver the shares of common stock to the 2022 Note holder upon exercise by such holder of its conversion rights under the 2022 Note; (iii) our loss of the “bid” price for its common stock and/or a market and such loss is not cured during the specified cure periods; and (iv) our failure to complete an uplisting of our Common Stock to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by April 30, 2024 (the “Uplist Transaction”). During the year ended September 2023, for no additional consideration, the 2022 Notes were amended several times in order to allow the Company to issue additional notes payable, extend the completion date for the Uplist Transaction, and amend certain provisions with regards to mandatory conversion of the notes upon the Uplist Transaction. In connection with the issuance of the 2022 Notes, the Company granted the 2022 Notes noteholders 425,555 9.94 5 1,470,000 63,834 315,000 31,510 10.06 5 108,000 271,000 The Company recorded 2022 Notes with total principal of $ 4,230,000 2,870,000 705,000 1,578,000 315,000 271,000 As of September 30, 2023, outstanding balance of the 2022 Notes payable was $ 4,230,000 710,897 3,519,103 On December 26, 2023, the Company issued a total of 2,000 18,280 On February 14, 2024, the Company entered into an amendment to the 2022 Notes, under which 95 % of the principal amount of the Notes shall automatically convert, upon the closing of an Uplist Transaction, as defined, with a conversion price of $ 0.50 per share, into pre-funded warrants with an exercise price of $ 0.000125 per share, exercisable immediately. In addition, the note holder shall receive a warrant to purchase 80 times the dollar amount of the notes that are converted, with an exercise price per share of $ 0.50 During the three and six months ended March 31, 2024, the Company amortized debt discount of $ 46,965 710,897 4,211,720 no	6. CONVERTIBLE NOTES PAYABLE, SENIOR SECURED SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED September 30, 2023 September 30, 2022 Senior Secured Convertible Promissory Notes (the “2022 Notes”, includes $ 96,000 $ 4,230,000 $ 4,230,000 Unamortized debt discount (710,897 ) (2,567,508 ) Net Balance 3,519,103 1,662,492 Current Balance (3,519,103 ) - Non-Current Balance - 1,662,492 In July 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited individual investors and issued Senior Secured Convertible Promissory Notes (the “2022 Notes”) in the aggregate of $ 4,230,000 3,525,000 705,000 The 2022 Notes are secured by tangible and intangible assets of the Company, bears interest at a rate of 10 9.14 In connection with the issuance of the 2022 Notes, the Company granted the 2022 Notes noteholders 425,562 9.94 5 1,470,000 63,842 315,000 31,510 10.06 5 219,894 555,414 The Company recorded 2022 Notes with total principal of $ 4,230,000 2,870,000 705,000 1,470,000 315,000 555,414 302,000 As of September 30, 2022, outstanding balance of the 2022 Notes payable was $ 4,230,000 2,567,508 1,662,492 1,857,000 4,230,000 710,897 3,519,103 96,000
Series 1 And 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
CONVERTIBLE NOTES PAYABLE	6. CONVERTIBLE NOTES PAYABLE, SERIES 2 CONVERTIBLE NOTES PAYABLE SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Series 2 Convertible Notes (converted in November 2023) $ - $ 450,000 On November 6, 2020, the Company issued its unsecured Series 2 10 450,000 450,000 On November 30, 2023, the Series 2 Convertible Notes of $ 450,000 137,946 52,918	8. CONVERTIBLE NOTES PAYABLE SCHEDULE OF CONVERTIBLE NOTES PAYABLE 2023 2022 Series 1 Convertible Notes (converted in July 2023) $ - $ 550,000 Series 2 Convertible Notes (converted in November 2023) 450,000 450,000 Total 450,000 1,000,000 Current Balance (450,000 ) (550,000 ) Non-Current Balance $ - $ 450,000 Series 1 Convertible Notes On June 4, 2020, the Company issued unsecured 10 550,000 The Series 1 Convertible Notes provide, among other things: (i) interest at a rate of 10 (ii) term of approximately three years (iii) allow for the Company’s ability to prepay the Series Convertible Notes, in whole or in part, at any time; (iv) allow the automatic conversion of the Series 1 Convertible Notes upon a change of control into shares of the Company’s common stock, at a conversion price of $ 54.00 (v) allow the holders to convert the principal of the Series 1 Convertible Notes, along with accrued interest, in whole or in part, into shares of common stock at the conversion price of $ 54.00 (vi) allow for the Company’s ability to convert all note obligations outstanding upon a qualified equity financing into shares of common stock at the corresponding price per share of the qualified equity financing; (vii) the Company’s ability to convert the principal of the Series 1 Convertible Notes, along with accrued interest, in whole or in part, into shares of Common Stock at the respective Conversion Price in the event the volume weighted average price (“VWAP”) of the Common Stock equals or exceeds $ 64.00 (viii) the Company’s ability to convert all outstanding Note Obligations into shares of Common Stock at the respective Conversion Price (an “In Kind Note Repayment”) in lieu of repaying the Note Obligations outstanding on the Maturity Date, subject to a conversion multiplier of 4.5 As of September 30, 2022, outstanding balance of the Series 1 Convertible Notes amounted to $ 550,000 During the year ended September 30, 2023, pursuant to the terms of the convertible notes agreement, the Company issued 59,912 550,000 168,918 718,918 Series 2 Convertible Notes On November 6, 2020, the Company issued its unsecured Series 2 10 1,050,000 As of September 30, 2021, outstanding balance of the Series 2 Convertible Notes amounted to $ 1,050,000 600,000 100,000 As of September 30, 2023 and 2022, outstanding balance of the Series 2 Convertible Notes amounted to $ 450,000 1,000,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES The principal components of the Company’s net deferred tax assets consisted of the following at September 30: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS 2023 2022 Net operating loss & charitable contribution carryforwards $ 12,905,738 $ 11,485,524 Capitalized expenditures 1,396,415 1,535,736 Research and experimentation credit carryforwards 1,014,466 946,246 Stock based compensation 1,491,338 1,427,946 Property and Equipment 1,531 2,616 Accrued expenses 746,143 162,191 Inventory allowance 51,463 70,805 Gross deferred tax assets 17,607,094 15,631,061 Deferred tax asset valuation allowance (17,607,094 ) (15,631,061 ) Net deferred tax assets $ - $ - The provision (benefit) for income taxes differs from the tax computed with the statutory federal income tax rate as follows: SCHEDULE OF PROVISION BENEFIT INCOME TAX RATE 2023 2022 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % Increase due to: State income taxes – net of federal benefit 0.24 % 3.65 % Permanent Differences: Stock based compensation - % (18.10 )% R&D, taken as a credit (0.16 )% (0.23 )% Adjustment to fair value of derivative 3.48 % 3.98 % Other - % (1.14 )% Change in Valuation Allowance (24.56 )% (9.16 )% Total Income Tax Provision (Benefit) - % - % As of September 30, 2023 and 2022, the Company had federal net operating loss carryforwards totaling approximately $ 48,200,000 42,700,000 21,750,000 26,444,000 20,945,000 679,000 626,000 As of September 30, 2023 and 2022, the Company had state net operating loss carryforwards of approximately $ 44,570,000 40,367,000 425,000 406,000 As the Company has not yet achieved profitable operations, management believes the tax benefits as of September 30, 2023 and 2022 did not satisfy the realization criteria set forth in FASB ASC Topic 740, Income Taxes 1,976,000 483,000 The Company experienced an ownership change as a result of the Merger described in Note 1, causing a limitation on the annual use of the net operating loss carryforwards, which are subject to a substantial annual limitation due to the ownership change limitations set forth in Internal Revenue Code Section 382 and similar state provisions. A formal Section 382 study has not been performed. As of September 30, 2023, the Company is open to examination in the U.S. federal and certain state jurisdictions for tax years ended September 30, 2023, 2022, 2021 and 2020. In addition, any loss years remain open to the extent that losses are available for carryover to future years. Therefore, the tax years ended 2010 through 2021 The Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted on March 27, 2020. The CARES Act affected items such as carryback periods for net operating losses, modifications to the net interest deduction limitations and changes to tax depreciation methods. The company has taken the CARES Act into consideration for the tax year ended September 30, 2023 and continues to evaluate the impact of the CARES act on the business.

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS DEFICIT	7. STOCKHOLDERS DEFICIT Common Stock In January 2024 certain shareholders of the Company exchanged a total of 300,000 300,073 0.001 5 2013 Stock Incentive Plan On September 1, 2023, a majority of shareholders approved the 2023 Stock Plan with 455,169 no On June 18, 2013, the Company established the 2013 Stock Incentive Plan (the “ 2013 Plan 185,571 Common Stock Options Stock compensation activity under the 2013 Plan for the six months ended March 31, 2024 follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2023 102,125 $ 38.00 5.58 $ - Awarded - - - - Forfeited/Cancelled (1,825 ) (67.00 ) - - Outstanding at December 31, 2023 100,300 38.00 4.00 11,000 Awarded - - - - Forfeited/Cancelled (12,025 ) (58.00 ) - - Outstanding at March 31, 2024 88,275 $ 35.00 5.00 - Vested at March 31, 2024 74,769 $ 39.00 3.50 - Vested and expected to vest at March 31, 2024 88,275 $ 35.00 5.00 - During the six months ended March 31, 2024 and 2023, the Company recorded stock compensation expense of $ 25,909 172,550 As of March 31, 2024, there is approximately $ 45,000 1.34 Restricted Stock For the three months ended March 31, 2024 and 2023, compensation expense recorded for the restricted stock awards was approximately $ 0 1,000 0 3,000 As of March 31, 2023, there was no unrecognized compensation expense related to unvested stock-based compensation arrangements granted under the 2013 Plan.	10. STOCKHOLDERS DEFICIT Common Stock During the year ended September 30, 2023, the Company issued 3,436,712 0.001 250 3,344,321 2,209,839 20,210 12,019 59,912 Common Stock Options Common Stock Options activity under the 2013 Plan for the year ended September 30, 2023 and 2022 follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Weighted Weighted Average Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2021 124,495 $ 58.00 1.86 $ 140,151 Awarded 6,625 $ 6.00 Forfeited/Cancelled (32,494 ) $ 70.00 Outstanding at September 30, 2022 98,626 $ 52.00 1.46 $ 16,900 Awarded 24,500 $ 8.00 — Forfeited/Cancelled (21,001 ) $ 68.00 — — Outstanding at September 30, 2023 102,125 $ 38.00 3.9 $ — Vested at September 30, 2023 82,940 $ 44.00 4.89 $ — Vested and expected to vest at September 30, 2023 102,125 $ 38.00 3.9 $ — During the year ended September 30, 2022, the Company granted 2,375 4,250 36 12 10.02 5 10 47,609 86.8 98.5 1.5 3.5 0 3.6 5.8 During the year ended September 30, 2023, the Company granted 20,875 3,625 36 12 8.02 5 10 156,275 102.8 103.4 3.8 4.0 0 4.1 5.8 Pursuant to the vesting terms of the stock options, Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the year ended September 30, 2023 and 2022 resulting from stock options awarded to the Company’s employees, directors and consultants was approximately $ 246,000 459,000 57,000 148,000 189,000 311,000 As of September 30, 2023, there is approximately $ 162,000 1.80 0 Common Stock Warrants Common Stock Warrants activity for the year ended September 30, 2023 and 2022 follows: SCHEDULE OF STOCK WARRANTS ACTIVITY Weighted Weighted Average Warrants Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2021 349,380 $ 53.28 1.8 $ - Awarded 457,072 $ 9.95 3.8 - Forfeited/Cancelled - $ - - - Outstanding at September 30, 2022 806,452 $ 28.72 2.9 $ - Awarded 25,572,245 $ 0.85 4.8 13,958,846 Exchanged (77,090 ) $ 106.47 - - Forfeited/Cancelled (17,605 ) $ 50.20 - - Outstanding at September 30, 2023 26,284,002 $ 0.85 4.8 $ 13,958,846 Vested at September 30, 2023 26,284,002 $ $ Vested and expected to vest at September 30, 2023 26,284,002 $ $ Restricted Stock On July 30, 2021, the Company awarded 750 250 On September 27, 2021, the Company awarded 1,500 Restricted stock activity in shares under the 2013 Plan for the years ended September 30, 2023 and 2022 follows: SCHEDULE OF RESTRICTED STOCK ACTIVITY 2023 2022 Non Vested at September 30, 2022 and 2021 250 2,250 Awarded — — Vested (250 ) (2,000 ) Forfeited — — Non Vested at September 30, 2023 and 2022 — 250 The weighted average restricted stock award date fair value information for the years ended September 30, 2023 and 2022 follows: SCHEDULE OF WEIGHTED AVERAGE RESTRICTED STOCK AWARD DATE FAIR VALUE 2023 2022 Non Vested at September 30, 2022 and 2021 $ 18.00 $ 19.76 Awarded - - Vested (18.00 ) (19.90 ) Forfeited - - Non Vested at September 30, 2023 and 2022 $ — $ 18.00 For the years ended September 30, 2023 and 2022 compensation expense recorded for the restricted stock awards was approximately $ 3,000 40,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company enters into various agreements containing standard indemnification provisions. The Company’s indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of September 30, 2023 and 2022, no amounts have been accrued related to such indemnification provisions. From time to time, the Company may be exposed to litigation in connection with its operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. MIT Licensing Agreement In December 2007, the Company entered into a license agreement with MIT pursuant to which the Company acquired an exclusive world-wide license to develop and commercialize technology related to self-assembling peptide compositions, and methods of making and using such compositions in medical and non-medical applications, including claims that cover the Company’s proposed products and methods of use thereof. The license also provides non-exclusive rights to additional intellectual property in the fields that cover the Company’s proposed products and methods of use thereof, in order to provide freedom to operate. The license provides the Company a right to sublicense the exclusively licensed intellectual property. The Company has not sublicensed the exclusively licensed intellectual property to any party for any field. In exchange for the licenses granted in the agreement, the Company has paid MIT license maintenance fees and patent prosecution costs. The Company paid license maintenance fees of $ 50,000 50,000 The Company is obligated to indemnify MIT and related parties from losses arising from claims relating to the exercise of any rights granted to the Company under the license, with certain exceptions. The maximum potential amount of future payments the Company could be required to make under this provision is unlimited. The Company considers there to be a low performance risk as of September 30, 2023. The agreement expires upon the expiration or abandonment of all patents that are issued and licensed to the Company by MIT under such agreement. The Company expects that patents will be issued from presently pending US and foreign patent applications. Any such patent will have a term of 20

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS From April 1, 2024 through April 3, 2024, the Company raised an additional $ 125,000 With respect to the $ 125,000 As of May 9, 2024, the Company had not been approved to be listed on a qualifying national exchange, had not repaid any advances, and had not received notice from any investors to receive pre-funded warrants and common warrants in lieu of prepayment. From April 12, 2024 through May 1, 2024, the Company raised an additional $ 600,000 20 In May 2024, the Company issued its convertible notes payable totaling $ 2,220,000 1,850,000 370,000 10 0.50 June 30, 2024 100 0.515625 On June 12, 2024, the Company completed a second closing of its convertible notes payable totaling $180,000, in exchange for cash of $150,000, net of original issue discount of $30,000. All other terms were identical to the convertible notes payable issued by the Company in May 2024.	12. SUBSEQUENT EVENTS In October and November 2023, the Company received shareholder advances in the aggregate of $ 450,000 On November 8, 2023, the Company entered into a Securities Purchase Agreement (the “PIPE SPA”) with certain institutional and accredited individual investors (collectively, the “Investors”) providing for the issuance and sale by the Company to the Investors of (i) pre-funded warrants (the “PIPE Pre-Funded Warrants”) and (ii) warrants (the “PIPE Common Warrants” and together with the PIPE Pre-Funded Warrants, the “PIPE Warrants”). The PIPE Warrants will be issued as part of a private placement offering authorized by the Company’s Board of Directors (the “PIPE Offering”). The estimated aggregate gross proceeds for the sale of the PIPE Warrants will be approximately $ 7.1 In November 2023, certain provisions of the Company’s Convertible Notes Payable, Senior Secured (See Note 6) and Exchange Notes (see Note 7) were amended to extend the date of the completion of an Uplist Transaction to March 15, 2024. In addition, upon effectivity of the Uplist Transaction, 50% of the then outstanding principal amount of the Convertible Notes Payable, Senior Secured and Exchange Notes shall automatically convert (the “Automatic Conversion”) into shares of Common Stock, with the conversion price for purposes of such Automatic Conversion of $ 4.00 6.3812 4.00 In November 2023, the Company amended the Second A&R Registration Rights Agreement to that certain Second Amended and Restated Registration Rights Agreement, dated as of May 15, 2023 to (I) extend the filing deadline by which the Company is obligated to file with the SEC a registration statement under the Securities Act of 1933, as amended, registering certain securities issued in the 2022 Convertible Note Offering to the earlier of (i) the date that is 30 days following the Uplist Transaction and (ii) January 31, 2024 (such date was subsequently extended to March 15, 2024), and (II) to provide for the inclusion of the Registerable Securities (as defined therein) in the Uplist S-1 (as defined therein). In November 2023, the Company also entered into an amendment to the Bridge SPA, with certain institutional and accredited individual investors that participated in the Bridge Offering. Under amendment, upon the closing of the next underwritten public offering of Common Stock (the “Qualifying Offering”), which the Company agreed is the Uplist Transaction, if the effective offering price to the public per share of Common Stock (the “Qualifying Offering Price”) is lower than $ 4.00 per share, then the Company shall issue additional Bridge Pre-Funded Warrants, or shares of Common Stock in lieu thereof to the extent necessary to cause the Company to meet the listing requirements of the Company’s proposed trading market in the Uplist Transaction, in an amount reflecting a reduction in the purchase price paid for the Bridge Shares and Bridge Pre-Funded Warrants that equals the proportion by which the Qualifying Offering Price is less than $ 4.00 . Condensed Consolidated Balance Sheets As of March 31, 2024 (Unaudited) and September 30, 2023 March 31, September 30, 2024 2023 (unaudited) ASSETS Current assets: Cash $ 26,426 $ 222,720 Inventory 1,329,593 1,364,504 Prepaid expenses and other current assets 177,158 362,866 Total current assets 1,533,177 1,950,090 Long-term assets: Property and equipment, net 3,390 4,599 Other assets 3,500 3,500 Total long-term assets 6,890 8,099 Total assets $ 1,540,067 $ 1,958,189 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 2,969,520 $ 2,304,207 Accrued interest 1,026,963 823,128 Shareholders advances related to bridge financing 1,125,000 - Accrued expenses and other liabilities 363,092 467,496 Insurance premium financing 34,755 243,285 Convertible notes payable, senior secured, current portion, net of discount 4,211,720 3,519,103 Convertible notes payable, unsecured, current portion, net of discount 2,686,501 1,658,702 Convertible notes payable, Series 2, unsecured, current portion - 450,000 Current portion of convertible note - 450,000 Total current liabilities 12,417,551 9,465,921 Commitments and contingencies - - Stockholders’ deficit: Preferred stock, $ 0.001 5,000,000 none - - Preferred stock Common stock, $ 0.001 350,000,000 4,444,364 4,689,446 4,444 4,689 Common stock 4,444 4,689 Additional paid-in capital 55,324,472 54,543,188 Accumulated deficit (66,206,400 ) (62,055,609 ) Total stockholders’ deficit (10,877,484 ) (7,507,732 ) Total liabilities and stockholders’ deficit $ 1,540,067 $ 1,958,189 The accompanying notes are an integral part of these condensed consolidated financial statements. Condensed Consolidated Statements of Operations (Unaudited) For the Three and Six Months Ended March 31, 2024 and 2023 2024 2023 2024 2023 For the three months ended For the six months ended March 31, March 31, March 31, March 31, 2024 2023 2024 2023 Revenue $ 31,866 $ 16,654 $ 77,733 $ 22,914 Operating expenses: Cost of revenues 21,555 18,718 45,161 36,353 Selling, general and administrative expenses 683,184 1,252,786 1,994,534 2,355,701 Research and development expenses 203,869 170,634 409,449 332,087 Total operating expenses 908,608 1,442,138 2,449,144 2,724,141 Loss from operations (876,742 ) (1,425,484 ) (2,371,411 ) (2,701,227 ) Other (expense) income: Interest expense (592,397 ) (635,190 ) (1,779,380 ) (1,159,503 ) Gain on extinguishment of derivative liabilities - 1,158,197 - 1,158,197 Total other (expense) income, net (592,397 ) 523,007 (1,779,380 ) (1,306 ) Net loss $ (1,469,139 ) $ (902,477 ) $ (4,150,791 ) $ (2,702,533 ) Net loss per common share - basic and diluted $ (0.33 ) $ (0.71 ) $ (0.90 ) $ (2.15 ) Weighted common shares - basic and diluted 4,497,111 1,263,585 4,602,623 1,258,099 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Condensed Consolidated Statements of Changes in Stockholders’ Deficit (Unaudited) For the Three and Six Months Ended March 31, 2024 and 2023 Preferred Amount Common Stock Amount Additional Paid- Accumulated Total Balance at September 30, 2023 - $ - 4,689,446 $ 4,689 $ 54,543,188 $ (62,055,609 ) $ (7,507,732 ) Net loss - - - - - (2,681,652 ) (2,681,652 ) Issuance of common stock upon conversion of convertible notes - - 52,918 53 587,906 - 587,959 Stock-based compensation expense - - - - 25,909 - 25,909 Balance at December 31, 2023 - - 4,742,364 4,742 55,157,003 (64,737,261 ) (9,575,516 ) Net loss - - - - - (1,469,139 ) (1,469,139 ) Issuance of common stock upon conversion of convertible notes - - 2,000 2 18,278 - 18,280 Issuance of warrants, net of financing costs - - - - 148,891 - 148,891 Exchange of common stock into warrants - - (300,000 ) (300 ) 300 - - Balance at March 31, 2024 - $ - 4,444,364 $ 4,444 $ 55,324,472 $ (66,206,400 ) $ (10,877,484 ) Balance at September 30, 2022 - $ - 1,252,734 $ 1,252 $ 50,878,718 $ (55,072,773 ) $ (4,192,803 ) Net loss - - - - - (1,800,056 ) (1,800,056 ) Stock-based compensation expense - - - - 104,026 - 104,026 Balance at December 31, 2022 - - 1,252,734 1,252 50,982,744 (56,872,829 ) (5,888,833 ) Balance - - 1,252,734 1,252 50,982,744 (56,872,829 ) (5,888,833 ) Net loss - - - - - (902,477 ) (902,477 ) Vesting of restricted stock - - 250 - - - - Issuance of common stock and warrants, net of financing costs - - 9,598 10 287,410 - 287,420 Exchange of warrants into common stock - - 12,019 13 49,265 - 49,278 Stock-based compensation expense - - - - 68,524 - 68,524 Balance at March 31, 2023 - $ - 1,274,601 $ 1,275 $ 51,387,943 $ (57,775,306 ) $ (6,386,088 ) Balance - $ - 1,274,601 $ 1,275 $ 51,387,943 $ (57,775,306 ) $ (6,386,088 ) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Condensed Consolidated Statements of Cash Flows (Unaudited) For the Six Months Ended March 31, 2024 and 2023 2024 2023 For the Six Months Ended March 31, March 31, 2024 2023 Cash flows from operating activities: Net loss $ (4,150,791 ) $ (2,702,533 ) Adjustments to reconcile net loss to cash used in operating activities: Depreciation 1,209 1,043 Stock-based compensation 25,909 172,550 Gain on extinguishment of derivative liabilities - (1,158,197 ) Accretion of discount and debt issuance costs on convertible notes payable 1,437,588 846,147 Changes in operating asset and liabilities: Inventory 34,911 12,464 Prepaid expenses and other current assets 185,707 280,058 Accounts payable 665,314 1,097,894 Accrued interest 341,793 313,356 Accrued expenses and other liabilities (104,404 ) (112,713 ) Net cash used in operating activities (1,562,764 ) (1,249,931 ) Cash flows from financing activities: Repayment of insurance premium financing (208,530 ) (212,514 ) Shareholder advances related to bridge financing 1,125,000 230,000 Proceeds from unsecured convertible notes 450,000 515,000 Net cash provided by financing activities 1,366,470 532,486 Net decrease in cash (196,294 ) (717,445 ) Cash, beginning of period 222,720 746,940 Cash, end of period $ 26,426 $ 29,495 Non-cash financing activities: Exchange of Senior Secured and Series 2 Convertible notes and accrued interest into common stock $ 606,239 $ - Relative fair value of warrants issued – fourth close $ 148,891 $ - Conversion of convertible notes and accrued interest to common stock, net $ 606,239 $ - Exchange of Series G and Series H warrants for common stock $ - $ 49,278 Issuance of restricted stock $ - $ 3,019 Fair value of warrants issued - second close $ - $ 256,439 Fair value of inducement shares issued - second close $ - $ 25,840 Fair value of placement agent warrants - second close $ - $ 28,093 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. ARCH THERAPEUTICS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX-MONTHS ENDED MARCH 31, 2024 AND 2023 (Unaudited)

SHAREHOLDER ADVANCES RELATED TO

SHAREHOLDER ADVANCES RELATED TO BRIDGE FINANCING	6 Months Ended
	Mar. 31, 2024
Shareholder Advances Related To Bridge Financing
SHAREHOLDER ADVANCES RELATED TO BRIDGE FINANCING	8. SHAREHOLDER ADVANCES RELATED TO BRIDGE FINANCING During the period ended March 31, 2024, the Company received $ 1,125,000 in shareholder advances provided as a partial prepayment of securities to be issued pursuant to a Securities Purchase Agreement dated November 8, 2023 (the “PIPE SPA”). 1,000,000 125,000 With respect to $ 1,000,000 125,000 As of May 9, 2024, the Company had not been approved to be listed on a qualifying national exchange, had not repaid any advances, and had not received notice from any investors to receive pre-funded warrants and common warrants in lieu of prepayment.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2024, and the results of its operations and its cash flows for the three and six months ended March 31, 2024 and 2023. The balance sheet as of September 30, 2023 is derived from the Company’s audited financial statements. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending September 30, 2024. In accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating decision maker (the Company’s President and Chief Executive Officer) determined that the Company has only one The condensed consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation.	Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1: 200 In accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating decision maker (the Company’s President and Chief Executive Officer) determined that the Company has only one
Use of Estimates	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.
Revenue	Revenue The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third-party warehouse. In circumstances where the transaction price is not able to be determined at the time of shipment, the Company does not recognize revenue or any receivable amount until such time that the final transaction price is established.	Revenue recognition In accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue upon shipment from the Company’s third-party warehouse which is when control of the product is transferred to the customers. In circumstances where the transaction price is not able to be determined at the time of shipment, the Company does not recognize revenue or any receivable amount until such time that the final transaction price is established and shipped to customer.
Cost of Revenue	Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense.	Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents as of September 30, 2023 and 2022.
Inventories		Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out (“FIFO”) basis. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The Company records adjustments to its inventory for estimated obsolescence or diminution in net realizable value equal to the difference between the cost of the inventory and the estimated net realizable value. When evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period in which it occurs. Once inventory has been written down, it creates a new cost basis for inventory that may not subsequently written up. For the year ended September 30, 2023 there was no 248,073
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.
Property and Equipment		Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with FASB ASC Topic 360, Property, Plant and Equipment
Leases		Leases The Company determines whether a contract is, or contains, a lease at inception. Operating lease right-of-use (“ ROU The Company leases its office facility on a month to month basis with a monthly lease of approximately $ 3,500
Derivative Liabilities		Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 .
Complex Financial Instruments		Complex Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option-pricing model or other acceptable valuation models, including Monte-Carlo simulations. Derivative instruments are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is re-assessed at the end of each reporting period. The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants, including options or warrants to non-employees in exchange for consulting or other services performed. The Company accounts for its common stock warrants in accordance with Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging
Income Taxes		Income Taxes In accordance with FASB ASC Topic 740, Income Taxes ASC 740 The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable.
Research and Development	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the Company’s awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the condensed consolidated financial statements, is based on awards that are ultimately expected to vest.	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of our awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the consolidated financial statements, is based on awards that are ultimately expected to vest.
Loss per Common Share	Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the periods ended March 31, 2024 and 2023, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES March 31, 2024 March 31, 2023 Stock options 88,275 104,325 Stock warrants 26,724,240 847,021 Convertible notes payable 754,744 721,790 Total 27,567,259 1,673,136	Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the years ended September 30, 2023 and 2022, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES September 30, 2023 September 30, 2022 Stock Options 102,125 98,626 Stock Warrants 26,284,002 806,452 Convertible notes payable 738,763 652,202 Unvested restricted common stock - 250 Total 27,124,890 1,557,530
Fair Value Measurements	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures At March 31, 2024 and September 30, 2023, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Series Convertible Notes, 2022 Notes, Second Notes, Third Notes and the Fourth Notes approximate fair value because borrowing rates and terms are similar to comparable market participants.	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company’s own views about the assumptions market participants would use in pricing the asset or liability. At September 30, 2023 and 2022, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Company’s convertible notes (see Notes 6,7, and 8) approximate fair value because borrowing rates and terms are similar to comparable market participants.
Financial Statement Reclassification		Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. During the year ended September 30, 2023, the Company reclassified the carrying amount of Exchange Notes of $ 699,781
Recent Accounting Pronouncements		Recent Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective October 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has not yet generated sufficient revenues to fund operations and relies on issuance of debt and equity instruments to generate working capital. As reflected in the accompanying financial statements, for the six months ended March 31, 2024, the Company recorded a net loss of $ 4,150,791 1,562,764 The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its current and its potential future products. The Company has not yet generated sufficient revenues to fund operations and relies on issuance of debt and equity instruments to generate working capital. In evaluating the going concern position of the Company, management has considered potential funding providers and believes that financing to fund future operations could be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.
Reverse stock split	Reverse stock split On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1: 200
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The Company has determined that the warrants issued in June 2018 and May 2019 equity financing (see Note 3) meet the requirements for liability classification. During the three months ended March 31, 2023, $ 1,158,197 12,019 49,278
Risks and uncertainties – Geopolitical Conflicts	Risks and uncertainties – Geopolitical Conflicts The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may be impacted by the outbreak of geopolitical conflicts. The Company’s ability to obtain future inventory may be impacted, therefore potentially affecting the Company’s future revenue stream. In addition, the Company has historically and principally funded its operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of Common Stock and warrants which may also be impacted by economic conditions beyond the Company’s control as well as uncertainties resulting from geopolitical conflicts. The extent to which recent events, including recent wars in Ukraine and Israel/Gaza, will impact the global economy and the Company is uncertain and cannot be reasonably measured.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES	For the periods ended March 31, 2024 and 2023, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES March 31, 2024 March 31, 2023 Stock options 88,275 104,325 Stock warrants 26,724,240 847,021 Convertible notes payable 754,744 721,790 Total 27,567,259 1,673,136	For the years ended September 30, 2023 and 2022, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES September 30, 2023 September 30, 2022 Stock Options 102,125 98,626 Stock Warrants 26,284,002 806,452 Convertible notes payable 738,763 652,202 Unvested restricted common stock - 250 Total 27,124,890 1,557,530

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories consist of the following: SCHEDULE OF INVENTORIES March 31, September 30, 2024 2023 Finished Goods $ 65,980 $ 40,969 Goods-in-Process 1,263,613 1,323,535 Total $ 1,329,593 $ 1,364,504	Inventories consist of the following: SCHEDULE OF INVENTORIES September 30, September 30, 2023 2022 Finished Goods $ 40,969 $ 9,063 Goods-in-process 1,323,535 1,405,785 Total $ 1,364,504 $ 1,414,848

WARRANT DERIVATIVE LIABILITY (T

WARRANT DERIVATIVE LIABILITY (Tables)	12 Months Ended
	Sep. 30, 2023
Warrant Derivative Liability
SCHEDULE OF FAIR VALUE MEASUREMENTS	Fair Value Measurements Using Significant Unobservable Inputs - Year Ended September 30, 2023 SCHEDULE OF FAIR VALUE MEASUREMENTS (Level 3) Series G Series H Total Beginning balance at September 30, 2022 $ 748,275 $ 459,200 $ 1,207,475 Exchange of warrants into common stock (13,947 ) (35,330 ) (49,277 ) Extinguishment of derivative liabilities (734,328 ) (423,870 ) (1,158,197 ) Ending balance at September 30, 2023 $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs - Year Ended September 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Beginning balance $ 1,000,000 $ 748,275 $ 459,200 Expiration of derivative liability (1,000,000 ) — — Ending balance at September 30, 2022 $ — $ 748,275 $ 459,200 Ending balance $ — $ 748,275 $ 459,200
SCHEDULE OF DERIVATIVE LIABILITIES	SCHEDULE OF DERIVATIVE LIABILITIES Series G Series H Series G Series H Date of valuation March 10, 2023 September 30, 2022 Closing price per share of Common Stock $ 4.10 $ 4.10 $ 3.84 $ 3.84 Exercise price per share $ 140.00 $ 80.00 $ 140.00 $ 80.00 Expected volatility 179.41 % 141.03 % 132.97 % 122.50 % Risk-free interest rate 4.91 % 4.75 % 4.05 % 4.14 % Dividend yield — — — — Valuation assumptions - - - - Remaining expected term of underlying securities (years) 0.24 1.31 0.69 1.57

CONVERTIBLE NOTES PAYABLE, SE_2

CONVERTIBLE NOTES PAYABLE, SENIOR SECURED (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Senior Secured Convertible Promissory Notes (the “2022 Notes”) $ 4,211,720 $ 4,230,000 Unamortized debt discount - (710,897 ) Net Balance $ 4,211,720 $ 3,519,103	SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED September 30, 2023 September 30, 2022 Senior Secured Convertible Promissory Notes (the “2022 Notes”, includes $ 96,000 $ 4,230,000 $ 4,230,000 Unamortized debt discount (710,897 ) (2,567,508 ) Net Balance 3,519,103 1,662,492 Current Balance (3,519,103 ) - Non-Current Balance - 1,662,492

CONVERTIBLE NOTES PAYABLE, UN_2

CONVERTIBLE NOTES PAYABLE, UNSECURED (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED	SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Senior Secured Convertible Promissory Notes (the “2022 Notes”) $ 4,211,720 $ 4,230,000 Unamortized debt discount - (710,897 ) Net Balance $ 4,211,720 $ 3,519,103	SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED September 30, 2023 September 30, 2022 Senior Secured Convertible Promissory Notes (the “2022 Notes”, includes $ 96,000 $ 4,230,000 $ 4,230,000 Unamortized debt discount (710,897 ) (2,567,508 ) Net Balance 3,519,103 1,662,492 Current Balance (3,519,103 ) - Non-Current Balance - 1,662,492
SCHEDULE OF SHARE BASED PAYMENT AWARD AND WARRANTS VALUATION ASSUMPTIONS		The warrants issued with the 2022 Notes, the Second Closing Notes, and the Third Closing Notes were valued using the Black Scholes option pricing model with the following assumptions: SCHEDULE OF SHARE BASED PAYMENT AWARD AND WARRANTS VALUATION ASSUMPTIONS Note Placement Note Placement Note First closing Second Closing Third Closing Note Placement Note Placement Note Date of valuation July 6, 2022 January 18, 2023 May 15, 2023 Closing price per share of Common Stock $ 9.98 $ 9.98 $ 5.76 $ 5.76 $ 2.77 Exercise price per share $ 9.94 $ 10.06 $ 9.94 $ 10.06 $ 9.94 Expected volatility 88.44 % 88.44 % 111.31 % 111.31 % 114.33 % Risk-free interest rate 2.96 % 2.96 % 3.43 % 3.43 % 3.46 % Dividend yield — — — — — Valuation assumptions - - - - - Remaining expected term of underlying securities (years) 5.0 5.0 5.0 5.0 5.0
Exchange Second and Third Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED	SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED March 31, 2024 September 30, 2023 Exchanged notes (July 2022) $ 699,781 $ 699,781 Second closing notes (January 2023) 636,000 636,000 Third closing notes (March, April, May, 2023) 702,720 702,720 Fourth closing notes (March, 2024) 648,000 - Total 2,686,501 2,038,501 Unamortized debt discount - (379,799 ) Net balance $ 2,686,501 $ 1,658,702	SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED September 30, 2023 September 30, 2022 Exchanged notes (July 2022) $ 699,781 $ 699,781 Second closing notes (January 2023) 636,000 - Third closing notes (March, April, May, 2023) 702,720 - Total 2,038,501 $ 699,781 Unamortized debt discount (379,799 ) - Net Balance 1,658,702 699,781 Current Balance (1,658,702 ) - Non-Current Balance - 699,781

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Senior Secured Convertible Promissory Notes (the “2022 Notes”) $ 4,211,720 $ 4,230,000 Unamortized debt discount - (710,897 ) Net Balance $ 4,211,720 $ 3,519,103	SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED September 30, 2023 September 30, 2022 Senior Secured Convertible Promissory Notes (the “2022 Notes”, includes $ 96,000 $ 4,230,000 $ 4,230,000 Unamortized debt discount (710,897 ) (2,567,508 ) Net Balance 3,519,103 1,662,492 Current Balance (3,519,103 ) - Non-Current Balance - 1,662,492
Series Convertible Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, 2024 September 30, 2023 Series 2 Convertible Notes (converted in November 2023) $ - $ 450,000	SCHEDULE OF CONVERTIBLE NOTES PAYABLE 2023 2022 Series 1 Convertible Notes (converted in July 2023) $ - $ 550,000 Series 2 Convertible Notes (converted in November 2023) 450,000 450,000 Total 450,000 1,000,000 Current Balance (450,000 ) (550,000 ) Non-Current Balance $ - $ 450,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS	The principal components of the Company’s net deferred tax assets consisted of the following at September 30: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS 2023 2022 Net operating loss & charitable contribution carryforwards $ 12,905,738 $ 11,485,524 Capitalized expenditures 1,396,415 1,535,736 Research and experimentation credit carryforwards 1,014,466 946,246 Stock based compensation 1,491,338 1,427,946 Property and Equipment 1,531 2,616 Accrued expenses 746,143 162,191 Inventory allowance 51,463 70,805 Gross deferred tax assets 17,607,094 15,631,061 Deferred tax asset valuation allowance (17,607,094 ) (15,631,061 ) Net deferred tax assets $ - $ -
SCHEDULE OF PROVISION BENEFIT INCOME TAX RATE	The provision (benefit) for income taxes differs from the tax computed with the statutory federal income tax rate as follows: SCHEDULE OF PROVISION BENEFIT INCOME TAX RATE 2023 2022 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % Increase due to: State income taxes – net of federal benefit 0.24 % 3.65 % Permanent Differences: Stock based compensation - % (18.10 )% R&D, taken as a credit (0.16 )% (0.23 )% Adjustment to fair value of derivative 3.48 % 3.98 % Other - % (1.14 )% Change in Valuation Allowance (24.56 )% (9.16 )% Total Income Tax Provision (Benefit) - % - %

STOCKHOLDERS DEFICIT (Tables)

STOCKHOLDERS DEFICIT (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	Stock compensation activity under the 2013 Plan for the six months ended March 31, 2024 follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2023 102,125 $ 38.00 5.58 $ - Awarded - - - - Forfeited/Cancelled (1,825 ) (67.00 ) - - Outstanding at December 31, 2023 100,300 38.00 4.00 11,000 Awarded - - - - Forfeited/Cancelled (12,025 ) (58.00 ) - - Outstanding at March 31, 2024 88,275 $ 35.00 5.00 - Vested at March 31, 2024 74,769 $ 39.00 3.50 - Vested and expected to vest at March 31, 2024 88,275 $ 35.00 5.00 -	Common Stock Options activity under the 2013 Plan for the year ended September 30, 2023 and 2022 follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Weighted Weighted Average Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2021 124,495 $ 58.00 1.86 $ 140,151 Awarded 6,625 $ 6.00 Forfeited/Cancelled (32,494 ) $ 70.00 Outstanding at September 30, 2022 98,626 $ 52.00 1.46 $ 16,900 Awarded 24,500 $ 8.00 — Forfeited/Cancelled (21,001 ) $ 68.00 — — Outstanding at September 30, 2023 102,125 $ 38.00 3.9 $ — Vested at September 30, 2023 82,940 $ 44.00 4.89 $ — Vested and expected to vest at September 30, 2023 102,125 $ 38.00 3.9 $ —
SCHEDULE OF STOCK WARRANTS ACTIVITY		Common Stock Warrants activity for the year ended September 30, 2023 and 2022 follows: SCHEDULE OF STOCK WARRANTS ACTIVITY Weighted Weighted Average Warrants Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2021 349,380 $ 53.28 1.8 $ - Awarded 457,072 $ 9.95 3.8 - Forfeited/Cancelled - $ - - - Outstanding at September 30, 2022 806,452 $ 28.72 2.9 $ - Awarded 25,572,245 $ 0.85 4.8 13,958,846 Exchanged (77,090 ) $ 106.47 - - Forfeited/Cancelled (17,605 ) $ 50.20 - - Outstanding at September 30, 2023 26,284,002 $ 0.85 4.8 $ 13,958,846 Vested at September 30, 2023 26,284,002 $ $ Vested and expected to vest at September 30, 2023 26,284,002 $ $
SCHEDULE OF RESTRICTED STOCK ACTIVITY		Restricted stock activity in shares under the 2013 Plan for the years ended September 30, 2023 and 2022 follows: SCHEDULE OF RESTRICTED STOCK ACTIVITY 2023 2022 Non Vested at September 30, 2022 and 2021 250 2,250 Awarded — — Vested (250 ) (2,000 ) Forfeited — — Non Vested at September 30, 2023 and 2022 — 250
SCHEDULE OF WEIGHTED AVERAGE RESTRICTED STOCK AWARD DATE FAIR VALUE		The weighted average restricted stock award date fair value information for the years ended September 30, 2023 and 2022 follows: SCHEDULE OF WEIGHTED AVERAGE RESTRICTED STOCK AWARD DATE FAIR VALUE 2023 2022 Non Vested at September 30, 2022 and 2021 $ 18.00 $ 19.76 Awarded - - Vested (18.00 ) (19.90 ) Forfeited - - Non Vested at September 30, 2023 and 2022 $ — $ 18.00

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Net loss	$ 1,469,139	$ 2,681,652	$ 902,477	$ 1,800,056	$ 4,150,791	$ 2,702,533	$ 6,982,836	$ 5,275,854
Cash used in operating activities					$ 1,562,764	$ 1,249,931	$ 3,374,216	$ 4,456,075

SCHEDULE OF BASIC AND DILUTED L

SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE POTENTIAL DILUTIVE SECURITIES (Details) - shares	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	27,567,259	1,673,136	27,124,890	1,557,530
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	88,275	104,325	102,125	98,626
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	26,724,240	847,021	26,284,002	806,452
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	754,744	721,790	738,763	652,202
Unvested Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total				250

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)		3 Months Ended				6 Months Ended		12 Months Ended
	Jan. 17, 2023	Mar. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)
Nonmonetary Transaction [Line Items]
Number of reporting units | Segment		1						1
Write-down of inventories		$ 0		$ 0					$ 248,073
Monthly lease								3,500
Carrying amount of exchange notes								699,781
Net loss		1,469,139	$ 2,681,652	902,477	$ 1,800,056	$ 4,150,791	$ 2,702,533	6,982,836	5,275,854
Cash used in operating activities						1,562,764	1,249,931	3,374,216	4,456,075
Gain loss on sale of derivatives				$ 1,158,197			$ 1,158,197
Series G and H Warrants [Member]
Nonmonetary Transaction [Line Items]
Issuance of common stock shares | shares				12,019
Fair value of warrants				$ 49,278
Series H Warrant [Member]
Nonmonetary Transaction [Line Items]
Gain loss on sale of derivatives				$ 1,158,197				$ 1,158,197
Reverse Stock Split [Member]
Nonmonetary Transaction [Line Items]
Common shares in ratio	200

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Finished Goods	$ 65,980	$ 40,969	$ 9,063
Goods-in-Process	1,263,613	1,323,535	1,405,785
Total	$ 1,329,593	$ 1,364,504	$ 1,414,848

INSURANCE PREMIUM FINANCING (De

INSURANCE PREMIUM FINANCING (Details Narrative) - Insurance Premium Financing [Member] - USD ($)	12 Months Ended
	Sep. 30, 2023	Mar. 31, 2024	Sep. 30, 2022
Short-Term Debt [Line Items]
Debt instrument, face amount	$ 395,000		$ 354,000
Interest rate	8.70%		2.99%
Periodic payment	$ 35,000
Short term debt	$ 243,285	$ 34,755	$ 247,933

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Offsetting Assets [Line Items]
Beginning balance	$ 1,207,475
Exchange of warrants into common stock	(49,277)
Extinguishment of derivative liabilities	(1,158,197)
Ending balance		$ 1,207,475
Series G Warrant [Member]
Offsetting Assets [Line Items]
Beginning balance	748,275	748,275
Exchange of warrants into common stock	(13,947)
Extinguishment of derivative liabilities	(734,328)
Ending balance		748,275
Expiration of derivative liability
Series H Warrant [Member]
Offsetting Assets [Line Items]
Beginning balance	459,200	459,200
Exchange of warrants into common stock	(35,330)
Extinguishment of derivative liabilities	(423,870)
Ending balance		459,200
Expiration of derivative liability
Series F Warrant [Member]
Offsetting Assets [Line Items]
Beginning balance		1,000,000
Ending balance
Expiration of derivative liability		$ (1,000,000)

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES (Details)	Mar. 10, 2023	Sep. 30, 2022
Series G Warrant [Member]
Offsetting Assets [Line Items]
Remaining expected term of underlying securities (years)	2 months 26 days	8 months 8 days
Series G Warrant [Member] | Measurement Input, Share Price [Member]
Offsetting Assets [Line Items]
Valuation assumptions	4.10	3.84
Series G Warrant [Member] | Measurement Input, Exercise Price [Member]
Offsetting Assets [Line Items]
Valuation assumptions	140	140
Series G Warrant [Member] | Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Valuation assumptions	179.41	132.97
Series G Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Valuation assumptions	4.91	4.05
Series G Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Valuation assumptions
Series H Warrant [Member]
Offsetting Assets [Line Items]
Remaining expected term of underlying securities (years)	1 year 3 months 21 days	1 year 6 months 25 days
Series H Warrant [Member] | Measurement Input, Share Price [Member]
Offsetting Assets [Line Items]
Valuation assumptions	4.10	3.84
Series H Warrant [Member] | Measurement Input, Exercise Price [Member]
Offsetting Assets [Line Items]
Valuation assumptions	80	80
Series H Warrant [Member] | Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Valuation assumptions	141.03	122.50
Series H Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Valuation assumptions	4.75	4.14
Series H Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Valuation assumptions

WARRANT DERIVATIVE LIABILITY (D

WARRANT DERIVATIVE LIABILITY (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 10, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021	May 12, 2019	Jun. 02, 2018	Jun. 22, 2017
Class of Warrant or Right [Line Items]
Gain loss on sale of derivatives			$ 1,158,197		$ 1,158,197
Series G and H Warrants [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock shares			12,019
Fair value of warrants			$ 49,278
Extinguishment of Derivative Liabilities For Warrants [Member]
Class of Warrant or Right [Line Items]
Stockholders equity period increase decrease						49,277
Derivative Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Derivative liabilities		$ 0		$ 0		$ 0	1,207,475	$ 2,207,475
Fair value adjustment of derivatives							$ 1,000,000
Series F Warrant [Member]
Class of Warrant or Right [Line Items]
Amount of cash											$ 36
Series G Warrant [Member]
Class of Warrant or Right [Line Items]
Amount of cash		$ 22		$ 22						$ 22
Class of warrant or right, exercised	34,013
Stock issued during period, shares, warrants exercised	3,402
Series H Warrant [Member]
Class of Warrant or Right [Line Items]
Amount of cash						$ 10.66			$ 10.66
Class of warrant or right, exercised	43,077
Stock issued during period, shares, warrants exercised	8,617
Gain loss on sale of derivatives			$ 1,158,197			$ 1,158,197

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE SENIOR SECURED (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Notes 2022 [Member]
Short-Term Debt [Line Items]
Long term debt, gross	$ 4,211,720	$ 4,230,000	$ 4,230,000
Unamortized debt discount		(710,897)	(2,567,508)
Net Balance	$ 4,211,720	3,519,103	1,662,492
Current Balance		(3,519,103)
Non-Current Balance			1,662,492
Unsecured Convertible Notes [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Long term debt, gross		$ 96,000	$ 96,000

CONVERTIBLE NOTES PAYABLE, SE_3

CONVERTIBLE NOTES PAYABLE, SENIOR SECURED (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 12, 2024	Dec. 26, 2023	Jan. 31, 2023	Jul. 31, 2022	Jan. 31, 2024	Jul. 31, 2022	Mar. 31, 2024	May 31, 2023	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	Feb. 14, 2024
Short-Term Debt [Line Items]
Amortized debt discount										$ 2,310,860	$ 302,049
Amortization of debt discount premium										(2,310,860)	(302,049)
The 2022 Offering [Member]
Short-Term Debt [Line Items]
Debt instrument Principal amount				$ 4,230,000		$ 4,230,000
Debt discount				2,870,000		2,870,000
Fair value of warrants				1,578,000		1,578,000
Common stock issued						315,000
Professional fees						555,414
Amortized debt discount						302,000
Amortization of debt discount premium						(302,000)
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Fair value of warrants				1,470,000		1,470,000
New issues of common stock			9,598					10,608
Common stock issued			$ 26,000	315,000				$ 18,000
Direct legal and professional fees				555,414
Placement Agent Warrants [Member]
Short-Term Debt [Line Items]
Fair value of warrants				219,894		219,894
Common Stock [Member]
Short-Term Debt [Line Items]
Term years					5 years
Common Stock [Member] | The 2022 Offering [Member]
Short-Term Debt [Line Items]
Professional fees						271,000
Warrant [Member] | The 2022 Offering [Member]
Short-Term Debt [Line Items]
Fair value of warrants				1,470,000		1,470,000
Warrant [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Direct legal and professional fees				271,000
Warrant [Member] | Placement Agent Warrants [Member]
Short-Term Debt [Line Items]
Fair value of warrants				$ 108,000		$ 108,000
Prefunded Warrants [Member]
Short-Term Debt [Line Items]
Exercisable per share	$ 0.001				$ 0.001
New issues of common stock					300,073
Prefunded Warrants [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
New issues of common stock	9,782
Warrant Shares [Member]
Short-Term Debt [Line Items]
Warrants to purchase of shares				425,555		425,555
Exercisable per share				$ 9.94		$ 9.94
Term years				5 years		5 years
New issues of common stock				63,834
Warrant Shares [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Warrants to purchase of shares				425,562		425,562
New issues of common stock				63,842
Placement Agent Warrants [Member]
Short-Term Debt [Line Items]
Warrants to purchase of shares			6,565	31,510		31,510
Exercisable per share			$ 10.06	$ 10.06		$ 10.06
Term years			5 years	5 years		5 years
Fair value of warrants			$ 13,000
Notes 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument Principal amount				$ 4,230,000		$ 4,230,000
Cash proceeds						3,525,000
Debt discount				$ 705,000		$ 705,000
Interest rate				10%		10%						95%
Conversion price				$ 9.14		$ 9.14						$ 0.50
Amortized debt discount							$ (46,965)		$ (710,897)	1,857,000
Amortized debt discount							4,211,720		4,211,720	4,230,000	4,230,000
Unamortized debt discount										710,897	2,567,508
Net amount							4,211,720		4,211,720	3,519,103	1,662,492
Amortization of debt discount premium							46,965		710,897	(1,857,000)
Unamortized debt discount										(710,897)	(2,567,508)
Notes 2022 [Member] | The 2022 Offering [Member]
Short-Term Debt [Line Items]
Debt discount				$ 705,000		$ 705,000
Notes 2022 [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Exercisable per share												0.50
Notes 2022 [Member] | Prefunded Warrants [Member]
Short-Term Debt [Line Items]
Exercisable per share												$ 0.000125
Officer And Director Notes [Member]
Short-Term Debt [Line Items]
Debt instrument Principal amount										$ 96,000	$ 96,000
Senior Secured Convertible Promissory Notes [Member]
Short-Term Debt [Line Items]
Debt instrument Principal amount		$ 18,280
New issues of common stock		2,000

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE UNSECURED (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Exchange Notes [Member]
Short-Term Debt [Line Items]
Total	$ 699,781	$ 699,781	$ 699,781
Second Closing Notes [Member]
Short-Term Debt [Line Items]
Total	636,000	636,000
Third Closing Notes [Member]
Short-Term Debt [Line Items]
Total	702,720	702,720
Exchange Second and Third Closing Notes [Member]
Short-Term Debt [Line Items]
Total	2,686,501	2,038,501	699,781
Unamortized debt discount		(379,799)
Net balance	2,686,501	1,658,702	699,781
Current Balance		(1,658,702)
Non-Current Balance			$ 699,781
Fourth Closing Notes [Member]
Short-Term Debt [Line Items]
Total	$ 648,000

SCHEDULE OF SHARE BASED PAYMENT

SCHEDULE OF SHARE BASED PAYMENT AWARD AND WARRANTS VALUATION ASSUMPTIONS (Details)	May 15, 2023 $ / shares	Jan. 18, 2023 $ / shares	Jul. 06, 2022 $ / shares
Third Closing Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Closing price per share of Common Stock	$ 2.77
Third Closing Notes [Member] | Measurement Input, Exercise Price [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions	9.94
Third Closing Notes [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions	1.1433
Third Closing Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions	0.0346
Third Closing Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions
Third Closing Notes [Member] | Measurement Input, Expected Term [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining expected term of underlying securities (years)	5 years
Note Holders [Member] | First Closing Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Closing price per share of Common Stock			$ 9.98
Note Holders [Member] | First Closing Notes [Member] | Measurement Input, Exercise Price [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			9.94
Note Holders [Member] | First Closing Notes [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			0.8844
Note Holders [Member] | First Closing Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			0.0296
Note Holders [Member] | First Closing Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions
Note Holders [Member] | First Closing Notes [Member] | Measurement Input, Expected Term [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining expected term of underlying securities (years)			5 years
Note Holders [Member] | Second Closing Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Closing price per share of Common Stock		$ 5.76
Note Holders [Member] | Second Closing Notes [Member] | Measurement Input, Exercise Price [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		9.94
Note Holders [Member] | Second Closing Notes [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		1.1131
Note Holders [Member] | Second Closing Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		0.0343
Note Holders [Member] | Second Closing Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions
Note Holders [Member] | Second Closing Notes [Member] | Measurement Input, Expected Term [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining expected term of underlying securities (years)		5 years
Placement Agent [Member] | First Closing Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Closing price per share of Common Stock			$ 9.98
Placement Agent [Member] | First Closing Notes [Member] | Measurement Input, Exercise Price [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			10.06
Placement Agent [Member] | First Closing Notes [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			0.8844
Placement Agent [Member] | First Closing Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions			0.0296
Placement Agent [Member] | First Closing Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions
Placement Agent [Member] | First Closing Notes [Member] | Measurement Input, Expected Term [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining expected term of underlying securities (years)			5 years
Placement Agent [Member] | Second Closing Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Closing price per share of Common Stock		$ 5.76
Placement Agent [Member] | Second Closing Notes [Member] | Measurement Input, Exercise Price [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		10.06
Placement Agent [Member] | Second Closing Notes [Member] | Measurement Input, Price Volatility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		1.1131
Placement Agent [Member] | Second Closing Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions		0.0343
Placement Agent [Member] | Second Closing Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Valuation assumptions
Placement Agent [Member] | Second Closing Notes [Member] | Measurement Input, Expected Term [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining expected term of underlying securities (years)		5 years

CONVERTIBLE NOTES PAYABLE, UN_3

CONVERTIBLE NOTES PAYABLE, UNSECURED (Details Narrative) - USD ($)				1 Months Ended						3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 12, 2024	Jan. 31, 2023	Jul. 31, 2022	Jan. 31, 2024	May 31, 2023	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Jul. 31, 2022	Mar. 31, 2024	May 31, 2023	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	May 12, 2024	Feb. 14, 2024	Nov. 30, 2023	Nov. 06, 2020
Short-Term Debt [Line Items]
Amortization of debt discount premium													$ 2,310,860	$ 302,049
Prefunded Warrants [Member]
Short-Term Debt [Line Items]
Prefunded warrants	$ 0.001			$ 0.001
Shares issued				300,073
The Second Offering [Member]
Short-Term Debt [Line Items]
Payment of financing and stock issuance costs		$ 31,000						$ 31,000
Third Closing Notes [Member]
Short-Term Debt [Line Items]
Payment of financing and stock issuance costs											$ 5,000
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding			$ 1,470,000						$ 1,470,000
Shares issued		9,598									10,608
Shares issued, value		$ 26,000	315,000								$ 18,000
Payment of financing and stock issuance costs			555,414
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Short-Term Debt [Line Items]
Shares issued	9,782
Fair value of prefunded warrants	$ 148,891
Securities Purchase Agreement [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Payment of financing and stock issuance costs			$ 271,000
Second Warrants [Member]
Short-Term Debt [Line Items]
Purchase of warrants		127,968						127,968
Prefunded warrants		$ 9.94						$ 9.94
Warrants and rights outstanding, term		5 years						5 years
Warrants and rights outstanding		$ 256,000						$ 256,000
Placement Agent Warrants [Member]
Short-Term Debt [Line Items]
Purchase of warrants		6,565	31,510					6,565	31,510
Prefunded warrants		$ 10.06	$ 10.06					$ 10.06	$ 10.06
Warrants and rights outstanding, term		5 years	5 years					5 years	5 years
Warrants and rights outstanding		$ 13,000						$ 13,000
Third Warrants [Member]
Short-Term Debt [Line Items]
Purchase of warrants	130,383				141,396						141,396
Prefunded warrants	$ 9.94				$ 9.94						$ 9.94
Warrants and rights outstanding, term	5 years				5 years						5 years
Warrants and rights outstanding					$ 164,000						$ 164,000
Series 2 Notes Converted To Senior Secured Convertible Notes [Member]
Short-Term Debt [Line Items]
Unsecured convertible promissory notes									$ 699,781
Maturity date									Jan. 06, 2024
Series 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt instrument face amount			$ 600,000						$ 600,000									$ 1,050,000
Accrued interest			99,781						99,781
Interest rate																		10%
Long term debt, gross													450,000	450,000
Net Balance													450,000	1,000,000			$ 450,000
Notes 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument face amount			$ 4,230,000						$ 4,230,000
Interest rate			10%						10%							95%
Maturity date									Jun. 30, 2024
Conversiion price			$ 9.14						$ 9.14							$ 0.50
Debt instrument, unamortized discount			$ 705,000						$ 705,000
Debt discount													(710,897)	(2,567,508)
Amortization of debt discount premium										(46,965)		(710,897)	1,857,000
Long term debt, gross										4,211,720		4,211,720	4,230,000	4,230,000
Net Balance										4,211,720		4,211,720	3,519,103	1,662,492
Unamortized discount										$ 0		$ 0	0
Notes 2022 [Member] | Prefunded Warrants [Member]
Short-Term Debt [Line Items]
Prefunded warrants																0.000125
Notes 2022 [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Prefunded warrants																$ 0.50
Unsecured Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt instrument face amount	$ 648,000	$ 636,000			$ 703,000	$ 703,000	$ 703,000	$ 636,000			$ 703,000
Interest rate	10%	10%			10%			10%			10%
Maturity date					Jun. 30, 2024
Conversiion price		$ 9.14			$ 9.14			$ 9.14			$ 9.14				$ 9.14
Proceeds from convertible debt	$ 450,000				$ 488,000	488,000	488,000	$ 530,000
Debt instrument, unamortized discount	$ 198,000	$ 106,000			215,000	$ 215,000	$ 215,000	$ 106,000			$ 215,000
Second and Third Closing Notes [Member]
Short-Term Debt [Line Items]
Debt instrument, unamortized discount					321,000						321,000			380,000
Warrants and rights outstanding					433,000						433,000
Shares issued, value					44,000
Payment of financing and stock issuance costs					36,000
Debt discount					$ 834,000						$ 834,000
Amortization of debt discount premium													$ 454,000
Long term debt, gross														2,039,000
Net Balance														$ 1,659,000

SCHEDULE OF CONVERTIBLE NOTES_3

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2024	Nov. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Series 1 Convertible Notes [Member]
Short-Term Debt [Line Items]
Long term debt, gross				$ 550,000
Series 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
Long term debt, gross			450,000	450,000
Net Balance		$ 450,000	450,000	1,000,000
Series 1 And 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
Long term debt, gross			450,000	1,000,000
Current Balance			(450,000)	(550,000)
Non-Current Balance				450,000
Notes 2022 [Member]
Short-Term Debt [Line Items]
Long term debt, gross	4,211,720		4,230,000	4,230,000
Current Balance			(3,519,103)
Non-Current Balance				1,662,492
Unamortized debt discount			(710,897)	(2,567,508)
Net Balance	$ 4,211,720		$ 3,519,103	$ 1,662,492

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)			12 Months Ended
	Nov. 30, 2023	Nov. 06, 2020	Sep. 30, 2023	Sep. 30, 2022	Mar. 10, 2023	Jul. 31, 2022	Sep. 30, 2021	Jun. 04, 2020
Conversion Of Series 1 Convertible Notes Into Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion			59,912
Debt conversion, original debt, amount			$ 550,000
Accrued interest			168,918
Debt conversion original debt amount interest and debt			718,918
Series 1 Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest rate								10%
Debt instrument, face amount								$ 5,500
Debt instrument conversion price								$ 54
Debt conversion, principal and accrued interest conversion multiple					$ 4.5
Convertible debt				$ 550,000
Series 1 Convertible Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument conversion price								$ 64
Series 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest rate		10%
Debt instrument, term		3 years
Series 2 Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest rate		10%
Debt instrument, face amount		$ 1,050,000				$ 600,000
Convertible debt			450,000				$ 1,050,000
Net Balance	$ 450,000		$ 450,000	1,000,000
Conversion osf shares	52,918
Series 2 Convertible Notes [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount		$ 450,000
Series 2 Notes Converted To Senior Secured Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt conversion, original debt, amount				600,000
Accrued interest	$ 137,946			$ 100,000

SCHEDULE OF COMPONENTS OF DEFER

SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Net operating loss & charitable contribution carryforwards	$ 12,905,738	$ 11,485,524
Capitalized expenditures	1,396,415	1,535,736
Research and experimentation credit carryforwards	1,014,466	946,246
Stock based compensation	1,491,338	1,427,946
Property and Equipment	1,531	2,616
Accrued expenses	746,143	162,191
Inventory allowance	51,463	70,805
Gross deferred tax assets	17,607,094	15,631,061
Deferred tax asset valuation allowance	(17,607,094)	(15,631,061)
Net deferred tax assets

SCHEDULE OF PROVISION BENEFIT I

SCHEDULE OF PROVISION BENEFIT INCOME TAX RATE (Details)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Expected income tax (benefit) at federal statutory rate	21%	21%
State income taxes – net of federal benefit	0.24%	3.65%
Stock based compensation		(18.10%)
R&D, taken as a credit	(0.16%)	(0.23%)
Adjustment to fair value of derivative	3.48%	3.98%
Other		(1.14%)
Change in Valuation Allowance	(24.56%)	(9.16%)
Total Income Tax Provision (Benefit)	(0.00%)	(0.00%)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Effective Income Tax Rate Reconciliation [Line Items]
Valuation allowance	$ 1,976,000	$ 483,000
Open tax year	2021
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	$ 48,200,000	42,700,000
Domestic Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Tax credit carryforward amount	679,000	626,000
Domestic Tax Jurisdiction [Member] | Expire in 2026 [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	21,750,000
Domestic Tax Jurisdiction [Member] | Indefinite Life Carryforwards [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	26,444,000	20,945,000
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	44,570,000	40,367,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Tax credit carryforward amount	$ 425,000	$ 406,000

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Outstanding, Option Shares Outstanding	100,300	102,125	98,626	124,495
Outstanding, Weighted Average Exercise Price	$ 38	$ 38	$ 52	$ 58
Outstanding, Weighted Average Remaining Contractual Term (Year)	5 years	4 years	3 years 10 months 24 days	1 year 5 months 15 days	1 year 10 months 9 days
Outstanding, Aggregate Intrinsic Value	$ 11,000		$ 16,900	$ 140,151
Awarded, Option Shares Outstanding			24,500	6,625
Awarded, Weighted Average Exercise Price			$ 8	$ 6
Forfeited/Cancelled, Option Shares Outstanding	(12,025)	(1,825)	(21,001)	(32,494)
Forfeited/Cancelled, Weighted Average Exercise Price	$ 58	$ 67	$ 68	$ 70
Outstanding, Option Shares Outstanding	88,275	100,300	102,125	98,626	124,495
Outstanding, Weighted Average Exercise Price	$ 35	$ 38	$ 38	$ 52	$ 58
Outstanding, Aggregate Intrinsic Value		$ 11,000		$ 16,900	$ 140,151
Vested, Option Shares Outstanding	74,769		82,940
Vested, Weighted Average Exercise Price	$ 39		$ 44
Vested, Weighted Average Remaining Contractual Term (Years)	3 years 6 months		4 years 10 months 20 days
Vested, Aggregate Intrinsic Value
Vested and expected to vest, Option Shares Outstanding	88,275		102,125
Vested and expected to vest, Weighted Average Exercise Price	$ 35		$ 38
Vested and expected to vest,Weighted Average Remaining Contractual Term (Years)	5 years		3 years 10 months 24 days
Vested and expected to vest, Aggregate Intrinsic Value
Outstanding, Weighted Average Remaining Contractual Term (Year)			5 years 6 months 29 days
Forfeited/Cancelled, Weighted Average Exercise Price	$ (58)	$ (67)	$ (68)	$ (70)

SCHEDULE OF STOCK WARRANTS ACTI

SCHEDULE OF STOCK WARRANTS ACTIVITY (Details) - Common Stock Warrants [Member] - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, awards	806,452	349,380
Outstanding, awards, weighted average exercise price	$ 28.72	$ 53.28
Outstanding, awards, weighted average contractual term (Year)	4 years 9 months 18 days	2 years 10 months 24 days	1 year 9 months 18 days
Outstanding, Aggregate Intrinsic Value
Awarded, awards (in shares)	25,572,245	457,072
Awarded, awards, weighted average exercise price	$ 0.85	$ 9.95
Awarded, awards, weighted average contractual term (Year)	4 years 9 months 18 days	3 years 9 months 18 days
Forfeited/Cancelled, awards (in shares)	17,605
Forfeited/Cancelled, awards, weighted average exercise price (in dollars per share)	$ 50.20
Awarded, Aggregate Intrinsic Value	$ 13,958,846
Exchanged, awards (in shares)	(77,090)
Exchanged, awards, weighted average exercise price	$ 106.47
Forfeited/Cancelled, awards (in shares)	(17,605)
Outstanding, awards	26,284,002	806,452	349,380
Outstanding, awards, weighted average exercise price	$ 0.85	$ 28.72	$ 53.28
Outstanding, Aggregate Intrinsic Value	$ 13,958,846
Vested, awards (in shares)	26,284,002
Vested and expected to vest, awards (in shares)	26,284,002

SCHEDULE OF RESTRICTED STOCK AC

SCHEDULE OF RESTRICTED STOCK ACTIVITY (Details) - The 2013 Plan [Member] - shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non Vested at September 30, 2022 and 2021	250	2,250
Awarded
Vested	(250)	(2,000)
Forfeited
Non Vested at September 30, 2023 and 2022		250

SCHEDULE OF WEIGHTED AVERAGE RE

SCHEDULE OF WEIGHTED AVERAGE RESTRICTED STOCK AWARD DATE FAIR VALUE (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity [Abstract]
Non Vested at September 30, 2022 and 2021	$ 18	$ 19.76
Awarded
Vested	(18)	(19.90)
Forfeited
Non Vested at September 30, 2023 and 2022		$ 18

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Sep. 01, 2023

Sep. 27, 2021

Jul. 30, 2021

Jan. 31, 2024

Mar. 31, 2024

Dec. 31, 2023

Mar. 31, 2023

Mar. 31, 2024

Mar. 31, 2023

Sep. 30, 2023

Sep. 30, 2022

Mar. 12, 2024

Jun. 18, 2013

Subsidiary, Sale of Stock [Line Items]

Common stock, par value

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Share-based compensation arrangement by share-based payment award, options, grants in period, gross

24,500

6,625

Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average exercise price

$ 8

$ 6

Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum

102.80%

86.80%

Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum

103.40%

98.50%

Share-based compensation arrangement by share-based payment award, fair value risk free interest rate, minimum

3.80%

1.50%

Share-based compensation arrangement by share-based payment award, fair value risk free interest rate, maximum

4%

3.50%

Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate

0%

0%

Share-based compensation arrangement by share-based payment award, options, vested, number of shares

74,769

82,940

Share based compensation

$ 25,909

$ 172,550

$ 249,555

$ 499,583

Prefunded Warrants [Member]

Subsidiary, Sale of Stock [Line Items]

Issuance of common stock shares

300,073

Exercisable per share

$ 0.001

$ 0.001

Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Warrants and rights outstanding, term

5 years

Research and Development Expense [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based payment arrangement, expense

57,000

148,000

General and Administrative Expense [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based payment arrangement, expense

$ 189,000

$ 311,000

Minimum [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term

4 years 1 month 6 days

3 years 7 months 6 days

Maximum [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term

5 years 9 months 18 days

5 years 9 months 18 days

Employees, Directors and Consultants [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based payment arrangement, expense

$ 246,000

$ 459,000

The 2013 Plan [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average exercise price

$ 8.02

$ 10.02

Share-based compensation arrangement by share-based payment award, options, grants in period, aggregate grant date fair value

$ 156,275

$ 47,609

Share-based payment arrangement, nonvested award, cost not yet recognized, amount

$ 45,000

$ 45,000

$ 162,000

Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition

1 year 4 months 2 days

1 year 9 months 18 days

Granted shares

0

The 2013 Plan [Member] | Board of Directors and Management [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, options, grants in period, gross

20,875

2,375

The 2013 Plan [Member] | Consultants [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, options, grants in period, gross

3,625

4,250

2013 Stock Incentive Plan [Member]

Subsidiary, Sale of Stock [Line Items]

Issuance of common stock shares

455,169

0

Granted shares

185,571

Series G and Series H Warrants [Member]

Subsidiary, Sale of Stock [Line Items]

Shares issued from exchange of warrants

12,019

Conversion of Series One Convertible Notes Into Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Debt conversion, converted instrument, shares issued

59,912

Second and Third Closing Notes [Member]

Subsidiary, Sale of Stock [Line Items]

Debt conversion, converted instrument, shares issued

20,210

Restricted Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock issued during period, shares, restricted stock award, gross

250

Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, options, vested, number of shares

250

Restricted Stock [Member] | The 2013 Plan [Member] | Share-Based Payment Arrangement, Employee [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted

750

Restricted Stock [Member] | The 2013 Plan [Member] | Consultants [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted

1,500

Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, award vesting period

36 months

36 months

Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member] | Board of Directors and Management [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, expiration period

10 years

10 years

Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member] | Consultants [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based compensation arrangement by share-based payment award, award vesting period

12 months

12 months

Share-based compensation arrangement by share-based payment award, expiration period

5 years

5 years

Restricted Shares [Member]

Subsidiary, Sale of Stock [Line Items]

Share-based payment arrangement, expense

$ 0

$ 1,000

$ 0

$ 3,000

$ 3,000

$ 40,000

All Stock Issuances [Member]

Subsidiary, Sale of Stock [Line Items]

Issuance of common stock shares

300,000

3,436,712

Financing Activities With Accredited Investors [Member]

Subsidiary, Sale of Stock [Line Items]

Issuance of common stock shares

3,344,321

Proceeds from issuance or sale of equity

$ 2,209,839

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Patents [Member]
Finite-lived intangible asset, useful life (year)	20 years
MIT Licensing Agreement [Member]
Contractual obligation	$ 50,000	$ 50,000
Other expenses	$ 50,000	$ 50,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)			1 Months Ended					3 Months Ended		12 Months Ended
	Apr. 03, 2024 USD ($)	Nov. 08, 2023 USD ($) $ / shares	May 31, 2024 USD ($) $ / shares	May 01, 2024 USD ($)	Apr. 30, 2024 USD ($)	Nov. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Subsequent Event [Line Items]
Inventory write down								$ 0	$ 0		$ 248,073
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from advances from investors						$ 450,000	$ 450,000
Proceeds from issuance or sale of equity		$ 7,100,000
Threshold of public offering price per share to trigger issuance of additional securities | $ / shares		$ 4
Uplist transaction, purchase price rate over price paid by investor		6.3812
Interest rate percentage			10%
Convertible notes payable totaling			$ 2,220,000
Exchange for cash			1,850,000
Convertible notes payable original issue discount			$ 370,000
Conversion price | $ / shares			$ 0.50
Maturity date			Jun. 30, 2024
Common stock to a national exchange percentage			100%
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion price | $ / shares			$ 0.515625
Subsequent Event [Member] | Three Investors [Member]
Subsequent Event [Line Items]
Proceeds from advances from investors					$ 125,000
Prepayments of investors	$ 125,000
Subsequent Event [Member] | Four Investors [Member]
Subsequent Event [Line Items]
Proceeds from advances from investors				$ 600,000
Subsequent Event [Member] | Four Investors [Member] | Senior Secured Note [Member]
Subsequent Event [Line Items]
Interest rate percentage				20%
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Threshold of public offering price per share to trigger issuance of additional securities | $ / shares		$ 4

SHAREHOLDER ADVANCES RELATED _2

SHAREHOLDER ADVANCES RELATED TO BRIDGE FINANCING (Details Narrative) - USD ($)				6 Months Ended
	May 02, 2024	Apr. 30, 2024	Apr. 02, 2024	Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Advances to affiliate				$ 1,125,000
Securities Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock transaction				$ 1,000,000
Securities Purchase Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock transaction	$ 125,000	$ 125,000	$ 1,000,000